<SEC-DOCUMENT>0001437749-23-033718.txt : 20231206
<SEC-HEADER>0001437749-23-033718.hdr.sgml : 20231206
<ACCEPTANCE-DATETIME>20231206060514
ACCESSION NUMBER:		0001437749-23-033718
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20231206
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231206
DATE AS OF CHANGE:		20231206

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioCardia, Inc.
		CENTRAL INDEX KEY:			0000925741
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				232753988
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38999
		FILM NUMBER:		231468349

	BUSINESS ADDRESS:	
		STREET 1:		320 SOQUEL WAY
		CITY:			SUNNYVALE
		STATE:			CA
		ZIP:			94085
		BUSINESS PHONE:		650-226-0123

	MAIL ADDRESS:	
		STREET 1:		320 SOQUEL WAY
		CITY:			SUNNYVALE
		STATE:			CA
		ZIP:			94085

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tiger X Medical, Inc.
		DATE OF NAME CHANGE:	20110616

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cardo Medical, Inc.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CLICKNSETTLE COM INC
		DATE OF NAME CHANGE:	20000823
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>bcda20231204_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:bcda="http://www.bcda.com/20231206"><head>
	<title>bcda20231204_8k.htm</title>

	<!-- Generated by ThunderDome Portal - 12/5/2023 3:17:54 AM -->
<meta http-equiv="Content-Type" content="text/html" /></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20238K" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20238K" name="dei:EntityCentralIndexKey">0000925741</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="bcda-20231206.xsd" xlink:type="simple" />
</ix:references>
<ix:resources>
<xbrli:context id="d20238K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000925741</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-12-06</xbrli:startDate>
<xbrli:endDate>2023-12-06</xbrli:endDate>
</xbrli:period>
</xbrli:context>

<xbrli:context id="d20238K_StatementClassOfStockAxis_CommonStockParValue0001">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000925741</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcda:CommonStockParValue0001CustomMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-12-06</xbrli:startDate>
<xbrli:endDate>2023-12-06</xbrli:endDate>
</xbrli:period>
</xbrli:context>

<xbrli:context id="d20238K_StatementClassOfStockAxis_WarrantToPurchaseCommonStock">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000925741</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcda:WarrantToPurchaseCommonStockCustomMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-12-06</xbrli:startDate>
<xbrli:endDate>2023-12-06</xbrli:endDate>
</xbrli:period>
</xbrli:context>



</ix:resources>
</ix:header>
</div>

<div style="font-family: Times New Roman; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><b>UNITED STATES</b></div>

<div style="font-family: Times New Roman; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: Times New Roman; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><b>FORM <ix:nonNumeric contextRef="d20238K" name="dei:DocumentType"><b>8-K</b></ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CURRENT REPORT</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Pursuant to Section</b>&#xa0;<b>13 or 15(d) of the Securities Exchange Act of 1934</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Date of Report (date of earliest event reported):&#xa0;<ix:nonNumeric contextRef="d20238K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">December&#xa0;6, 2023</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: Times New Roman; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><ix:nonNumeric contextRef="d20238K" name="dei:EntityRegistrantName"><b>BIOCARDIA, INC.</b></ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20238K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><b>Delaware</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20238K" name="dei:EntityFileNumber"><b>001-38999</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20238K" name="dei:EntityTaxIdentificationNumber"><b>23-2753988</b></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(State or other jurisdiction of</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">incorporation)</div>
			</td>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Commission File No.)</div>
			</td>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(IRS Employer Identification</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Number)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20238K" name="dei:EntityAddressAddressLine1"><b>320 Soquel Way</b></ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20238K" name="dei:EntityAddressCityOrTown"><b>Sunnyvale</b></ix:nonNumeric>, <ix:nonNumeric contextRef="d20238K" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince"><b>California</b></ix:nonNumeric> <ix:nonNumeric contextRef="d20238K" name="dei:EntityAddressPostalZipCode"><b>94085</b></ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Address of principal executive offices)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(<ix:nonNumeric contextRef="d20238K" name="dei:CityAreaCode"><b>650</b></ix:nonNumeric>)</b>&#xa0;<ix:nonNumeric contextRef="d20238K" name="dei:LocalPhoneNumber"><b>226-0120</b></ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:<br />
<br />
<ix:nonNumeric contextRef="d20238K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br />
<br />
<ix:nonNumeric contextRef="d20238K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br />
<br />
<ix:nonNumeric contextRef="d20238K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric>&#xa0;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br />
<br />
<ix:nonNumeric contextRef="d20238K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric>&#xa0;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0" />
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Securities registered pursuant to Section&#xa0;12(b) of the Act:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-width: 1px; border-style: solid; border-color: rgb(0, 0, 0); vertical-align: top; width: auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Title of each class</div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: auto; border-top: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Trading symbols</div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: auto; border-top: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Name of each exchange on which registered</div>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: auto; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20238K_StatementClassOfStockAxis_CommonStockParValue0001" name="dei:Security12bTitle">Common Stock, par value $0.001</ix:nonNumeric></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: auto; border-right: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20238K_StatementClassOfStockAxis_CommonStockParValue0001" name="dei:TradingSymbol">BCDA</ix:nonNumeric></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: auto; border-right: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The <ix:nonNumeric contextRef="d20238K_StatementClassOfStockAxis_CommonStockParValue0001" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric> Capital Market</div>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: auto; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20238K_StatementClassOfStockAxis_WarrantToPurchaseCommonStock" name="dei:Security12bTitle">Warrant to Purchase Common Stock</ix:nonNumeric></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: auto; border-right: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20238K_StatementClassOfStockAxis_WarrantToPurchaseCommonStock" name="dei:TradingSymbol">BCDAW</ix:nonNumeric></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: auto; border-right: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The <ix:nonNumeric contextRef="d20238K_StatementClassOfStockAxis_WarrantToPurchaseCommonStock" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric> Capital Market</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#xa0;230.405 of this chapter) or Rule&#xa0;12b-2&#xa0;of the Securities Exchange Act of 1934&#xa0;(&#167;&#xa0;240.12b-2&#xa0;of this chapter).</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Emerging growth company&#xa0;&#xa0;<ix:nonNumeric contextRef="d20238K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#xa0;13(a) of the Exchange Act.&#xa0;&#xa0;&#9744;&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 8.01 Other Events.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On December&#xa0;6, 2023, BioCardia, Inc. (the &#8220;Company&#8221;) entered into an At The Market Offering Agreement (the &#8220;Sales Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC (&#8220;HCW&#8221;). Under the Sales Agreement, the Company may offer and sell its common stock, par value $0.001 per share (&#8220;Common Stock&#8221;), from time to time having an aggregate offering price of up to $2.75 million (the &#8220;Shares&#8221;) during the term of the Sales Agreement through or to HCW as sales agent or principal. The Company has filed a prospectus supplement relating to the offer and sale of the Shares pursuant to the Sales Agreement. The offering and sale of the Shares will be made pursuant to the Company&#8217;s previously filed and effective Registration Statement on Form S-3 (File No. 333-275099), which was initially filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on October 19, 2023 and declared effective on December&#xa0;5, 2023. The Company intends to use the net proceeds from the offering, if any, for working capital and general corporate purposes, which include, but are not limited to, advancing its investigational biotherapeutic candidates and its biotherapeutic delivery partnering business.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company is not obligated to sell any Shares pursuant to the Sales Agreement. Subject to the terms and conditions of the Sales Agreement, HCW will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of The Nasdaq Capital Market (&#8220;Nasdaq&#8221;), to sell Shares from time to time based upon the Company&#8217;s instructions, including any price, time or size limits or other customary parameters or conditions the Company may impose.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the Sales Agreement, HCW may sell Shares by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415 of the Securities Act of 1933, as amended, and the rules and regulations thereunder.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Sales Agreement may be terminated by either party providing notice, subject to the limitations set forth in the Sales Agreement.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has agreed to pay HCW a commission equal to 3.0% of the gross proceeds from the sales of Shares pursuant to the Sales Agreement and has agreed to provide HCW with customary indemnification and contribution rights.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The foregoing summary of the Sales Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Sales Agreement, a copy of which is filed as Exhibit 1.1 hereto and incorporated herein by reference. The Sales Agreement contains representations and warranties that the parties made to, and solely for the benefit of, the other in the context of all of the terms and conditions of the Sales Agreement and in the context of the specific relationship between the parties. The provisions of the Sales Agreement, including the representations and warranties contained therein, are not for the benefit of any party other than the parties to the Sales Agreement and are not intended as a document for investors and the public to obtain factual information about the Company&#8217;s current state of affairs. Rather, investors and the public should look to other disclosures contained in the Company&#8217;s filings with the SEC.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any Shares under the Sale Agreement, nor shall there be any sale of such Shares in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Forward-Looking Statements</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certain information in this Current Report on Form&#xa0;8-K&#xa0;may be considered &#8220;forward-looking statements&#8221; within the meaning of Section&#xa0;27A of the Securities Act of 1933, as amended, and Section&#xa0;21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the Company&#8217;s sale of Shares under the Sales Agreement. These forward-looking statements are based on management&#8217;s current expectations, assumptions, hopes, beliefs, intentions and strategies regarding future events and are based on currently available information as to the outcome and timing of future events. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements, including due to changes in economic and financial conditions, such as volatility in interest and exchange rates and in the capital or credit markets, and due to other factors discussed in the section titled &#8220;Risk Factors&#8221; in our Annual Report and Quarterly Reports and other documents filed with the SEC from time to time. Except as otherwise required by applicable law, the Company disclaims any duty to update any forward-looking statements.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 9.01 Financial Statements and Exhibits.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(d) Exhibits.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exhibit</b>&#xa0;<b>No.</b></div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 92%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Description</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.1</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
			<td style="vertical-align: bottom; width: 92%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_602831.htm" style="-sec-extract:exhibit;">At The Market Offering Agreement, dated December&#xa0;6, 2023, by and between BioCardia, Inc. and H.C. Wainwright &amp; Co., LLC</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5.1</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
			<td style="vertical-align: bottom; width: 92%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_602766.htm" style="-sec-extract:exhibit;">Opinion of Wilson Sonsini Goodrich &amp; Rosati, Professional Corporation.</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">23.1</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
			<td style="vertical-align: bottom; width: 92%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_602766.htm" style="-sec-extract:exhibit;">Consent of Wilson Sonsini Goodrich &amp; Rosati, Professional Corporation (included in Exhibit 5.1).</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">104</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
			<td style="vertical-align: bottom; width: 92%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#xa0;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">&#xa0;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 40%;">&#xa0;</td>
			<td colspan="2" style="vertical-align: top; width: 4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>BIOCARDIA, INC.</b></div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 40%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: December&#xa0;6, 2023</div>
			</td>
			<td style="vertical-align: top; width: 4%;">&#xa0;</td>
			<td style="vertical-align: bottom; width: 55%;">&#xa0;</td>
			<td style="vertical-align: top; width: 1%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 40%;">&#xa0;</td>
			<td style="vertical-align: top; width: 4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 55%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/&#xa0;Peter Altman, Ph.D.</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 40%;">&#xa0;</td>
			<td style="vertical-align: top; width: 4%;">&#xa0;</td>
			<td style="vertical-align: top; width: 55%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Peter Altman, Ph.D.</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 40%;">&#xa0;</td>
			<td style="vertical-align: top; width: 4%;">&#xa0;</td>
			<td style="vertical-align: top; width: 55%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President and Chief Executive&#xa0;Officer</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#xa0;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ex_602831.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<html><head>
	<title>ex_602831.htm</title>

	<!-- Generated by ThunderDome Portal - 12/5/2023 8:23:12 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 1.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>AT THE MARKET OFFERING AGREEMENT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">December 6, 2023</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">H.C. Wainwright &amp; Co., LLC<br>
430 Park Avenue<br>
New York, New York 10022</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Ladies and Gentlemen:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">BioCardia, Inc., a corporation organized under the laws of Delaware (the &#8220;<u>Company</u>&#8221;), confirms its agreement (this &#8220;<u>Agreement</u>&#8221;) with H.C. Wainwright &amp; Co., LLC (the &#8220;<u>Manager</u>&#8221;) as follows:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">1.&nbsp;&nbsp;&nbsp;&nbsp;<u>Definitions</u>. The terms that follow, when used in this Agreement and any Terms Agreement, shall have the meanings indicated.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Accountants</u>&#8221;&nbsp;shall have the meaning ascribed to such term in Section 4(m).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Act</u>&#8221; shall mean the Securities Act of 1933, as amended, and the rules and regulations of the Commission promulgated thereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Action</u>&#8221; shall have the meaning ascribed to such term in Section 3(p).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Affiliate</u>&#8221; shall have the meaning ascribed to such term in Section 3(o).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Applicable Time</u>&#8221; shall mean, with respect to any Shares, the time of sale of such Shares pursuant to this Agreement or any relevant Terms Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Base Prospectus</u>&#8221; shall mean the base prospectus contained in the Registration Statement at the Execution Time.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Board</u>&#8221; shall have the meaning ascribed to such term in Section 2(b)(iii).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Broker Fee</u>&#8221; shall have the meaning ascribed to such term in Section&nbsp;2(b)(v).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Business Day</u>&#8221; shall mean any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed; <u>provided</u>, <u>however</u>, that, for purposes of clarity, commercial banks shall not be deemed to be authorized or required by law to remain closed due to &#8220;stay at home&#8221;, &#8220;shelter-in-place&#8221;, &#8220;non-essential employee&#8221;&nbsp; or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are open for use by customers on such day.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Commission</u>&#8221; shall mean the United States Securities and Exchange Commission.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: justify;">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="2" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="2" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Common Stock</u>&#8221; shall have the meaning ascribed to such term in Section 2.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Common Stock Equivalents</u>&#8221; shall have the meaning ascribed to such term in Section 3(g).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Company Counsel</u>&#8221; shall have the meaning ascribed to such term in Section&nbsp;4(l).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>DTC</u>&#8221; shall have the meaning ascribed to such term in Section 2(b)(vii).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Effective Date</u>&#8221; shall mean each date and time that the Registration Statement and any post-effective amendment or amendments thereto became or becomes effective.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Exchange Act</u>&#8221; shall mean the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission promulgated thereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Execution Time</u>&#8221; shall mean the date and time that this Agreement is executed and delivered by the parties hereto.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Free Writing Prospectus</u>&#8221; shall mean a free writing prospectus, as defined in Rule&nbsp;405, that is used in connection with the issuance and sale of Shares under this Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>GAAP</u>&#8221; shall have the meaning ascribed to such term in Section 3(m).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Incorporated Documents</u>&#8221; shall mean the documents or portions thereof filed with the Commission on or prior to the Effective Date that are incorporated by reference in the Registration Statement or the Prospectus and any documents or portions thereof filed with the Commission after the Effective Date that are deemed to be incorporated by reference in the Registration Statement or the Prospectus.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Intellectual Property Rights</u>&#8221; shall have the meaning ascribed to such term in Section 3(v).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Issuer Free Writing Prospectus</u>&#8221; shall mean an issuer free writing prospectus, as defined in Rule&nbsp;433, that is used in connection with the issuance and sale of Shares under this Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Losses</u>&#8221; shall have the meaning ascribed to such term in Section 7(d).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Material Adverse Effect</u>&#8221; shall have the meaning ascribed to such term in Section&nbsp;3(b).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Material Permits</u>&#8221; shall have the meaning ascribed to such term in Section 3(t).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Net Proceeds</u>&#8221; shall have the meaning ascribed to such term in Section&nbsp;2(b)(v).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Permitted Free Writing Prospectus</u>&#8221; shall have the meaning ascribed to such term in Section 4(g).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="font-size: 10pt; font-family: Times New Roman; text-align: center;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Placement</u>&#8221; shall have the meaning ascribed to such term in Section 2(c).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Proceeding</u>&#8221; shall have the meaning ascribed to such term in Section 3(b).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Prospectus</u>&#8221; shall mean the Base Prospectus, as supplemented by any subsequently filed Prospectus Supplement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Prospectus Supplement</u>&#8221; shall mean each prospectus supplement relating to the Shares prepared and filed pursuant to Rule&nbsp;424(b) from time to time.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Registration Statement</u>&#8221; shall mean the shelf registration statement (File Number&nbsp;333-275099) on Form&nbsp;S-3, including exhibits and financial statements and any prospectus supplement relating to the Shares that is filed with the Commission pursuant to Rule&nbsp;424(b) and deemed part of such registration statement pursuant to Rule&nbsp;430B, as amended on each Effective Date and, in the event any post-effective amendment thereto becomes effective, shall also mean such registration statement as so amended.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Representation Date</u>&#8221; shall have the meaning ascribed to such term in Section&nbsp;4(k).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Required Approvals</u>&#8221; shall have the meaning ascribed to such term in Section&nbsp;3(e).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Rule</u><u>&nbsp;</u><u>158</u>&#8221;, &#8220;<u>Rule</u><u>&nbsp;</u><u>164</u>&#8221;, &#8220;<u>Rule</u><u>&nbsp;</u><u>172</u>&#8221;, &#8220;<u>Rule</u><u>&nbsp;</u><u>173</u>&#8221;, &#8220;<u>Rule</u><u>&nbsp;</u><u>405</u>&#8221;, &#8220;<u>Rule</u><u>&nbsp;</u><u>415</u>&#8221;, &#8220;<u>Rule</u><u>&nbsp;</u><u>424</u>&#8221;, &#8220;<u>Rule</u><u>&nbsp;</u><u>430B</u>&#8221; and &#8220;<u>Rule</u><u>&nbsp;</u><u>433</u>&#8221; refer to such rules under the Act.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Sales Notice</u>&#8221; shall have the meaning ascribed to such term in Section&nbsp;2(b)(i).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>SEC Reports</u>&#8221; shall have the meaning ascribed to such term in Section 3(m).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Settlement Date</u>&#8221; shall have the meaning ascribed to such term in Section&nbsp;2(b)(vii).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Subsidiary</u>&#8221; shall have the meaning ascribed to such term in Section 3(a).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Terms Agreement</u>&#8221; shall have the meaning ascribed to such term in Section 2(a).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Time of Delivery</u>&#8221; shall have the meaning ascribed to such term in Section 2(c).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Trading Day</u>&#8221; means a day on which the Trading Market is open for trading.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Trading Market</u>&#8221; means the Nasdaq Capital Market.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.&nbsp;&nbsp;&nbsp;&nbsp;<u>Sale and Delivery of Shares</u>. The Company proposes to issue and sell through or to the Manager, as sales agent and/or principal, from time to time during the term of this Agreement and on the terms set forth herein, up to such number of shares (the &#8220;<u>Shares</u>&#8221;) of the Company&#8217;s common stock, $0.001&nbsp;par value per share (&#8220;<u>Common Stock</u>&#8221;), that does not exceed (a) the number or dollar amount of shares of Common Stock registered on the Prospectus Supplement, pursuant to which the offering is being made, (b) the number of authorized but unissued shares of Common Stock (less the number of shares of Common Stock issuable upon exercise, conversion or exchange of any outstanding securities of the Company or otherwise reserved from the Company&#8217;s authorized capital stock), or (c) the number or dollar amount of shares of Common Stock that would cause the Company or the offering of the Shares to not satisfy the eligibility and transaction requirements for use of Form S-3, including, if applicable, General Instruction I.B.6 of Registration Statement on Form S-3 (the lesser of (a), (b) and (c), the &#8220;<u>Maximum Amount</u>&#8221;). Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitations set forth in this Section 2 on the number and aggregate sales price of Shares issued and sold under this Agreement shall be the sole responsibility of the Company and that the Manager shall have no obligation in connection with such compliance.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="font-size: 10pt; font-family: Times New Roman; text-align: center;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Appointment of Manager as Selling Agent; Terms Agreement</u>. For purposes of selling the Shares through the Manager, the Company hereby appoints the Manager as exclusive agent of the Company for the purpose of selling the Shares of the Company pursuant to this Agreement and the Manager agrees to use its commercially reasonable efforts to sell the Shares on the terms and subject to the conditions stated herein. The Company agrees that, whenever it determines to sell the Shares directly to the Manager as principal, it will enter into a separate agreement (each, a &#8220;<u>Terms Agreement</u>&#8221;) in substantially the form of <u>Annex I</u> hereto, relating to such sale in accordance with Section&nbsp;2 of this Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Agent Sales</u>. Subject to the terms and conditions and in reliance upon the representations and warranties herein set forth, the Company will issue and agrees to sell Shares from time to time through the Manager, acting as sales agent, and the Manager agrees to use its commercially reasonable efforts to sell, as sales agent for the Company, on the following terms:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt; text-align: justify; text-indent: 27pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;The Shares are to be sold on a daily basis or otherwise as shall be agreed to by the Company and the Manager on any day that (A)&nbsp;is a Trading Day, (B)&nbsp;the Company has instructed the Manager by telephone (confirmed promptly by electronic mail) to make such sales (&#8220;<u>Sales Notice</u>&#8221;) and (C) the Company has satisfied its obligations under Section 6 of this Agreement. The Company will designate the maximum amount of the Shares to be sold by the Manager daily (subject to the limitations set forth in Section 2(d)) and the minimum price per Share at which such Shares may be sold. Subject to the terms and conditions hereof, the Manager shall use its commercially reasonable efforts to sell on a particular day all of the Shares designated for the sale by the Company on such day. The gross sales price of the Shares sold under this Section&nbsp;2(b) shall be the market price for the shares of Common Stock sold by the Manager under this Section&nbsp;2(b) on the Trading Market at the time of sale of such Shares.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt; text-indent: 27pt; text-align: justify;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;The Company acknowledges and agrees that (A)&nbsp;there can be no assurance that the Manager will be successful in selling the Shares, (B)&nbsp;the Manager will incur no liability or obligation to the Company or any other person or entity if it does not sell the Shares for any reason other than a failure by the Manager to use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable law and regulations to sell such Shares as required under this Agreement, and (C)&nbsp;the Manager shall be under no obligation to purchase Shares on a principal basis pursuant to this Agreement, except as otherwise specifically agreed by the Manager and the Company pursuant to a Terms Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="font-size: 10pt; font-family: Times New Roman; text-align: center;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt; text-indent: 27pt; text-align: justify;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall not authorize the issuance and sale of, and the Manager shall not be obligated to use its commercially reasonable efforts to sell, any Share at a price lower than the minimum price therefor designated from time to time by the Company&#8217;s Board of Directors (the &#8220;<u>Board</u>&#8221;), or a duly authorized committee thereof, or such duly authorized officers of the Company, and notified to the Manager in writing. The Company or the Manager may, upon notice to the other party hereto by telephone (confirmed promptly by electronic mail), suspend the offering of the Shares for any reason and at any time; <u>provided</u>, <u>however</u>, that such suspension or termination shall not affect or impair the parties&#8217; respective obligations with respect to the Shares sold hereunder prior to the giving of such notice.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt; text-indent: 27pt; text-align: justify;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;The Manager may sell Shares by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule&nbsp;415 under the Act, including without limitation sales made directly on the Trading Market, on any other existing trading market for the Common Stock or to or through a market maker. The Manager may also sell Shares in privately negotiated transactions, provided that the Manager receives the Company&#8217;s prior written approval for any sales in privately negotiated transactions and if so provided in the &#8220;Plan of Distribution&#8221; section of the Prospectus Supplement or a supplement to the Prospectus Supplement or a new Prospectus Supplement disclosing the terms of such privately negotiated transaction.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt; text-indent: 27pt; text-align: justify;">(v)&nbsp;&nbsp;&nbsp;&nbsp;The compensation to the Manager for sales of the Shares under this Section 2(b) shall be a placement fee of 3.0% of the gross sales price of the Shares sold pursuant to this Section 2(b) (&#8220;<u>Broker Fee</u>&#8221;). The foregoing rate of compensation shall not apply when the Manager acts as principal, in which case the Company may sell Shares to the Manager as principal at a price agreed upon at the relevant Applicable Time pursuant to a Terms Agreement. The remaining proceeds, after deduction of the Broker Fee and deduction of any transaction fees imposed by any clearing firm, execution broker, or governmental or self-regulatory organization in respect of such sales, shall constitute the net proceeds to the Company for such Shares (the &#8220;<u>Net Proceeds</u>&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt; text-indent: 27pt; text-align: justify;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;The Manager shall provide written confirmation (which may be by electronic mail) to the Company following the close of trading on the Trading Market each day in which the Shares are sold under this Section 2(b) setting forth the number of the Shares sold on such day, the aggregate gross sales proceeds and the Net Proceeds to the Company, and the compensation payable by the Company to the Manager with respect to such sales.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="font-size: 10pt; font-family: Times New Roman; text-align: center;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt; text-indent: 27pt; text-align: justify;">(vii)&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise agreed between the Company and the Manager, settlement for sales of the Shares will occur at 10:00 a.m. (New York City time) on the second (2nd) Trading Day (and on and after May 28, 2024, on the first (1st) Trading Day (or such later date on which the Commission&#8217;s final rule with respect to the shortening of the securities transaction settlement cycle becomes effective), or any such other settlement cycle as may be in effect pursuant to Rule 15c6-1 under the Exchange Act from time to time) following the date on which such sales are made (each, a &#8220;<u>Settlement Date</u>&#8221;). On or before the Trading Day prior to each Settlement Date, the Company will, or will cause its transfer agent to, electronically transfer the Shares being sold by crediting the Manager&#8217;s or its designee&#8217;s account (provided that the Manager shall have given the Company written notice of such designee at least one Trading Day prior to the Settlement Date) at The Depository Trust Company (&#8220;<u>DTC</u>&#8221;) through its Deposit and Withdrawal at Custodian System or by such other means of delivery as may be mutually agreed upon by the parties hereto which Shares in all cases shall be freely tradable, transferable, registered shares in good deliverable form. On each Settlement Date, the Manager will deliver the related Net Proceeds in same day funds to an account designated by the Company. The Company agrees that, if the Company, or its transfer agent (if applicable), defaults in its obligation to deliver duly authorized Shares on a Settlement Date, in addition to and in no way limiting the rights and obligations set forth in Section 7 hereto, the Company will (i) hold the Manager harmless against any loss, claim, damage, or reasonable, documented expense (including reasonable and documented legal fees and expenses), as incurred, arising out of or in connection with such default by the Company, and (ii) pay to the Manager any commission, discount or other compensation to which the Manager would otherwise have been entitled absent such default.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt; text-indent: 27pt; text-align: justify;">(viii)&nbsp;&nbsp;&nbsp;&nbsp;At each Applicable Time, Settlement Date, and Representation Date, the Company shall be deemed to have affirmed each representation and warranty contained in this Agreement as if such representation and warranty were made as of such date (except to the extent that any such representation or warranty is made as of a specified date, in which case such representation or warranty shall have been true and correct as of such date), modified as necessary to relate to the Registration Statement and the Prospectus as amended as of such date. Any obligation of the Manager to use its commercially reasonable efforts to sell the Shares on behalf of the Company shall be subject to the continuing accuracy of the representations and warranties of the Company herein, to the performance by the Company of its obligations hereunder and to the continuing satisfaction of the additional conditions specified in Section 6 of this Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt; text-indent: 27pt; text-align: justify;">(ix)&nbsp;&nbsp;&nbsp;&nbsp;If the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<u>Distribution</u>&#8221; and the record date for the determination of stockholders entitled to receive the Distribution, the &#8220;<u>Record Date</u>&#8221;), the Company hereby covenants that, in connection with any sales of Shares pursuant to a Sales Notice on the Record Date, the Company shall issue and deliver such Shares to the Manager on the Record Date and the Record Date shall be the Settlement Date and the Company shall cover any additional costs of the Manager in connection with the delivery of Shares on the Record Date.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="font-size: 10pt; font-family: Times New Roman; text-align: center;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Term Sales</u>. If the Company wishes to sell the Shares pursuant to this Agreement in a manner other than as set forth in Section 2(b) of this Agreement (each, a &#8220;<u>Placement</u>&#8221;), the Company will notify the Manager of the proposed terms of such Placement. If the Manager, acting as principal, wishes to accept such proposed terms (which it may decline to do for any reason in its sole discretion) or, following discussions with the Company wishes to accept amended terms, the Manager and the Company will enter into a Terms Agreement setting forth the terms of such Placement. The terms set forth in a Terms Agreement will not be binding on the Company or the Manager unless and until the Company and the Manager have each executed such Terms Agreement accepting all of the terms of such Terms Agreement. In the event of a conflict between the terms of this Agreement and the terms of a Terms Agreement, the terms of such Terms Agreement will control. A Terms Agreement may also specify certain provisions relating to the reoffering of such Shares by the Manager. The commitment of the Manager to purchase the Shares pursuant to any Terms Agreement shall be deemed to have been made on the basis of the representations and warranties of the Company herein contained and shall be subject to the terms and conditions herein set forth. Each Terms Agreement shall specify the number of the Shares to be purchased by the Manager pursuant thereto, the price to be paid to the Company for such Shares, any provisions relating to rights of, and default by, underwriters acting together with the Manager in the reoffering of the Shares, and the time and date (each such time and date being referred to herein as a &#8220;<u>Time of Delivery</u>&#8221;) and place of delivery of and payment for such Shares. Such Terms Agreement shall also specify any requirements for opinions of counsel, accountants&#8217; letters and officers&#8217; certificates pursuant to Section 6 of this Agreement and any other information or documents required by the Manager.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Maximum Number of Shares</u>. Under no circumstances shall the Company cause or request the offer or sale of any Shares if, after giving effect to the sale of such Shares, the aggregate amount of Shares sold pursuant to this Agreement would exceed the lesser of (A) together with all sales of Shares under this Agreement, the Maximum Amount, (B) the amount available for offer and sale under the currently effective Registration Statement and (C) the amount authorized from time to time to be issued and sold under this Agreement by the Board, a duly authorized committee thereof or a duly authorized executive committee, and notified to the Manager in writing. Under no circumstances shall the Company cause or request the offer or sale of any Shares pursuant to this Agreement at a price lower than the minimum price authorized from time to time by the Board, a duly authorized committee thereof or a duly authorized executive officer, and notified to the Manager in writing. Further, under no circumstances shall the Company cause or permit the aggregate offering amount of Shares sold pursuant to this Agreement to exceed the Maximum Amount.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="font-size: 10pt; font-family: Times New Roman; text-align: center;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Regulation M Notice</u>. Unless the exceptive provisions set forth in Rule&nbsp;101(c)(1) of Regulation&nbsp;M under the Exchange Act are satisfied with respect to the Shares, the Company shall give the Manager at least one (1) Business Day&#8217;s prior notice of its intent to sell any Shares in order to allow the Manager time to comply with Regulation&nbsp;M.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">3.&nbsp;&nbsp;&nbsp;<u>Representations and Warranties</u>. The Company represents and warrants to, and agrees with, the Manager at the Execution Time and on each such time that the following representations and warranties are repeated or deemed to be made pursuant to this Agreement, as set forth below, except as set forth in the Registration Statement, the Prospectus or the Incorporated Documents.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Subsidiaries</u>. The Company owns, directly or indirectly, all of the capital stock or other equity interests of each subsidiary that constitutes a &#8220;significant subsidiary&#8221; as defined in Rule 1-02 of Regulation S-X under the Exchange Act (individually, a &#8220;Subsidiary&#8221;) free and clear of any &#8220;<u>Liens</u>&#8221; (which for purposes of this Agreement shall mean a lien, charge, security interest, encumbrance, right of first refusal, preemptive right or other restriction), and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Organization and Qualification</u>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in violation nor in default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, would not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of this Agreement, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, from that set forth in the Registration Statement, the Base Prospectus, any Prospectus Supplement, the Prospectus or the Incorporated Documents, or (iii) a material adverse effect on the Company&#8217;s ability to perform in any material respect on a timely basis its obligations under this Agreement (any of (i), (ii) or (iii), a &#8220;<u>Material Adverse Effect</u>&#8221;) and no &#8220;<u>Proceeding</u>&#8221; (which for purposes of this Agreement shall mean any action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether commenced or threatened) has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="font-size: 10pt; font-family: Times New Roman; text-align: center;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Authorization and Enforcement</u>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise to carry out its obligations hereunder. The execution and delivery of this Agreement by the Company and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, the Board or the Company&#8217;s stockholders in connection herewith other than in connection with the Required Approvals. This Agreement has been duly executed and delivered by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#8217; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>No Conflicts</u>. The execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Shares and the consummation by it of the transactions contemplated hereby do not and will not (i) conflict with or violate any provision of the Company&#8217;s or any Subsidiary&#8217;s certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Filings, Consents and Approvals.</u> The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other &#8220;Person&#8221; (defined as an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind, including the Trading Market) in connection with the execution, delivery and performance by the Company of this Agreement, other than (i) the filings required by this Agreement, (ii) the filing with the Commission of the Prospectus Supplement, (iii) the filing of application(s) to and approval by the Trading Market for the listing of the Shares for trading thereon in the time and manner required thereby, and (iv) such filings as are required to be made under applicable state securities laws and the rules and regulations of the Financial Industry Regulatory Authority, Inc. (&#8220;<u>FINRA</u>&#8221;) (collectively, the &#8220;<u>Required Approvals</u>&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="font-size: 10pt; font-family: Times New Roman; text-align: center;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Issuance of Shares</u>. The Shares are duly authorized and, when issued and paid for in accordance with this Agreement, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock a sufficient number of shares of Common Stock issuable pursuant to this Agreement. The issuance by the Company of the Shares has been registered under the Act and all of the Shares are freely transferable and tradable by the purchasers thereof without restriction (other than any restrictions arising solely from an act or omission of such a purchaser). The Shares are being issued pursuant to the Registration Statement and the issuance of the Shares has been registered by the Company under the Act. The &#8220;<u>Plan of Distribution</u>&#8221; section within the Registration Statement permits the issuance and sale of the Shares as contemplated by this Agreement. Upon receipt of the Shares, the purchasers of such Shares will have good and marketable title to such Shares and the Shares will be freely tradable on the Trading Market.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(g)&nbsp;&nbsp;&nbsp;&nbsp;<u>Capitalization</u>. The authorized capital stock of the Company conforms to the description thereof set forth in the Registration Statement and the Prospectus. Except as disclosed in the SEC Reports and except as pursuant to this Agreement, the Company has not issued any capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant to the exercise of employee stock options and the vesting of restricted stock awards under the Company&#8217;s equity incentive plans, the issuance of shares of Common Stock or stock options to employees and consultants pursuant to the Company&#8217;s equity incentive plans or employee stock purchase plan and pursuant to the conversion and/or exercise of securities exercisable, exchangeable or convertible into Common Stock (&#8220;<u>Common Stock Equivalents</u>&#8221;) outstanding as of the date of the most recently filed periodic report under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by this Agreement. Except as set forth in the SEC Reports and except as pursuant to this Agreement, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance and sale of the Shares will not obligate the Company or any Subsidiary to issue shares of Common Stock or other securities to any Person. There are no outstanding securities or instruments of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon an issuance of securities by the Company or any Subsidiary. There are no outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The Company does not have any stock appreciation rights or &#8220;phantom stock&#8221; plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. No further approval or authorization of any stockholder, the Board or others is required for the issuance and sale of the Shares. There are no stockholders agreements, voting agreements or other similar agreements with respect to the Company&#8217;s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company&#8217;s stockholders.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="" style="font-size: 10pt; font-family: Times New Roman; text-align: center;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(h)&nbsp;&nbsp;&nbsp;&nbsp;<u>Registration Statement</u>. The Company meets the requirements for use of Form&nbsp;S-3 under the Act and has prepared and filed with the Commission the Registration Statement, including a related Base Prospectus, for registration under the Act of the offering and sale of the Shares. Such Registration Statement is effective and available for the offer and sale of the Shares as of the date hereof. As filed, the Base Prospectus contains all information required by the Act and the rules thereunder, and, except to the extent the Manager shall agree in writing to a modification, shall be in all substantive respects in the form furnished to the Manager prior to the Execution Time or prior to any such time this representation is repeated or deemed to be made. The Registration Statement, at the Execution Time, each such time this representation is repeated or deemed to be made, and at all times during which a prospectus is required by the Act to be delivered (whether physically or through compliance with Rule&nbsp;172, 173 or any similar rule) in connection with any offer or sale of the Shares, meets the requirements set forth in Rule&nbsp;415(a)(1)(x). The initial Effective Date of the Registration Statement was not earlier than the date three years before the Execution Time. The Company meets the transaction requirements as set forth in General Instruction I.B.1 of Form S-3 or, if applicable, as set forth in General Instruction I.B.6 of Form S-3 with respect to the aggregate market value of securities being sold pursuant to this offering and during the twelve (12) months prior to this offering.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Accuracy of Incorporated Documents</u>. The Incorporated Documents, when they were filed with the Commission, conformed in all material respects to the requirements of the Exchange Act and the rules thereunder, and none of the Incorporated Documents, when they were filed with the Commission, contained any untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein, in light of the circumstances under which they were made not misleading; and any further documents so filed and incorporated by reference in the Registration Statement, the Base Prospectus, the Prospectus Supplement or the Prospectus, when such documents are filed with the Commission, will conform in all material respects to the requirements of the Exchange Act and the rules thereunder, as applicable, and will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(j)&nbsp;&nbsp;&nbsp;&nbsp;<u>Ineligible Issuer</u>. (i)&nbsp;At the earliest time after the filing of the Registration Statement that the Company or another offering participant made a bona fide offer (within the meaning of Rule&nbsp;164(h)(2)) of the Shares and (ii)&nbsp;as of the Execution Time and on each such time this representation is repeated or deemed to be made (with such date being used as the determination date for purposes of this clause&nbsp;(ii)), the Company was not and is not an Ineligible Issuer (as defined in Rule&nbsp;405), without taking account of any determination by the Commission pursuant to Rule&nbsp;405 that it is not necessary that the Company be considered an Ineligible Issuer.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(k)&nbsp;&nbsp;&nbsp;&nbsp;<u>Free Writing Prospectus</u>. The Company is eligible to use Issuer Free Writing Prospectuses. Any Issuer Free Writing Prospectus does not include any information the substance of which conflicts with the information contained in the Registration Statement, including any Incorporated Documents and any prospectus supplement deemed to be a part thereof that has not been superseded or modified; and each Issuer Free Writing Prospectus does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The foregoing sentence does not apply to statements in or omissions from any Issuer Free Writing Prospectus based upon and in conformity with written information furnished to the Company by the Manager specifically for use therein. Any Issuer Free Writing Prospectus that the Company is required to file pursuant to Rule 433(d) has been, or will be, filed with the Commission in accordance with the requirements of the Act and the rules thereunder. Each Issuer Free Writing Prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) or that was prepared by or behalf of or used by the Company complies or will comply in all material respects with the requirements of the Act and the rules thereunder. The Company will not, without the prior consent of the Manager, prepare, use or refer to, any Issuer Free Writing Prospectuses.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(l)&nbsp;&nbsp;&nbsp;&nbsp;<u>Proceedings Related to Registration Statement</u>. The Registration Statement is not the subject of a pending proceeding or examination under Section&nbsp;8(d) or 8(e) of the Act, and the Company is not the subject of a pending proceeding under Section&nbsp;8A of the Act in connection with the offering of the Shares. The Company has not received any notice that the Commission has issued or intends to issue a stop-order with respect to the Registration Statement or that the Commission otherwise has suspended or withdrawn the effectiveness of the Registration Statement, either temporarily or permanently, or intends or has threatened in writing to do so.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(m)&nbsp;&nbsp;&nbsp;&nbsp;<u>SEC Reports</u>. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the one year preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus and the Prospectus Supplement, being collectively referred to herein as the &#8220;<u>SEC Reports</u>&#8221;) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Act and the Exchange Act, as applicable, and, since December 31, 2022 (including, without limitation, the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022), none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (&#8220;<u>GAAP</u>&#8221;), except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(n)&nbsp;&nbsp;&nbsp;&nbsp;[RESERVED]</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(o)&nbsp;&nbsp;&nbsp;&nbsp;<u>Material Changes; Undisclosed Events, Liabilities or Developments</u>. Since the date of the latest audited financial statements included within the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the date on which this representation is being made, (i) there has been no event, occurrence or development that has had or that would reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company&#8217;s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock, (v) the Company has not issued any equity securities to any officer, director or &#8220;<u>Affiliate</u>&#8221; (defined as any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 144 under the Act), except pursuant to existing Company stock incentive plans, and (vi) no executive officer of the Company or member of the Board has resigned from any position with the Company. The Company does not have pending before the Commission any request for confidential treatment of information. Except for the issuance of the Shares contemplated by this Agreement or as set forth in the SEC Reports, no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed at least one (1) Trading Day prior to the date that this representation is made.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="13" data-prefix="" data-suffix="" style="font-size: 10pt; font-family: Times New Roman; text-align: center;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(p)&nbsp;&nbsp;&nbsp;&nbsp;<u>Litigation</u>. Except as set forth in the SEC Reports, there is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &#8220;<u>Action</u>&#8221;), which, (i) adversely affects or challenges the legality, validity or enforceability of this Agreement or the issuance of the Shares hereunder or (ii) would, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Except as set forth in the SEC Reports, neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty that is required to be set forth in the SEC Reports which (i) adversely affects or challenges the legality, validity or enforceability of this Agreement or the issuance of the Shares hereunder or (ii) would, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Except as set forth in the SEC Reports, there has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Act.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(q)&nbsp;&nbsp;&nbsp;&nbsp;<u>Labor Relations</u>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company, which would reasonably be expected to result in a Material Adverse Effect. None of the Company&#8217;s or its Subsidiaries&#8217; employees is a member of a union that relates to such employee&#8217;s relationship with the Company or such Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all applicable U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="14" data-prefix="" data-suffix="" style="font-size: 10pt; font-family: Times New Roman; text-align: center;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(r)&nbsp;&nbsp;&nbsp;&nbsp;<u>Compliance</u>. Except as set forth in the SEC Reports, neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case as would not have or reasonably be expected to result in a Material Adverse Effect.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(s)&nbsp;&nbsp;&nbsp;&nbsp;<u>Environmental Laws</u>.The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, &#8220;<u>Hazardous Materials</u>&#8221;) into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (&#8220;<u>Environmental Laws</u>&#8221;); (ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and (iii), the failure to so comply would be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(t)&nbsp;&nbsp;&nbsp;&nbsp;<u>Regulatory Permits</u>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except where the failure to possess such permits would not reasonably be expected to result in a Material Adverse Effect (&#8220;<u>Material Permits</u>&#8221;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(u)&nbsp;&nbsp;&nbsp;&nbsp;<u>Title to Assets</u>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="15" data-prefix="" data-suffix="" style="font-size: 10pt; font-family: Times New Roman; text-align: center;">15</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(v)&nbsp;&nbsp;&nbsp;&nbsp;<u>Intellectual Property</u>. To the Company&#8217;s knowledge, the Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights owned or licensed by the Company or the Subsidiaries and necessary or required for use in connection with their respective businesses as described in the SEC Reports since December 31, 2022 (including, without limitation, the Company&#8217;s annual report on Form 10-K for the fiscal year ended December 31, 2022) and which the failure to do so have would have a Material Adverse Effect (collectively, the &#8220;<u>Intellectual Property Rights</u>&#8221;). None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement, except for expirations, terminations or abandonments which would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included within the SEC Reports, a written notice of a claim that the operation of their businesses violate or infringe upon the rights, including, without limitation, the Intellectual Property Rights of any Person, except as would not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their Intellectual Property Rights, except where failure to do so would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(w)&nbsp;&nbsp;&nbsp;&nbsp;<u>Insurance</u>. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not limited to, directors and officers insurance coverage. Neither the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(x)&nbsp;&nbsp;&nbsp;&nbsp;<u>Affiliate Transactions</u>. Except as set forth in the SEC Reports, none of the officers or directors of the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment of salary or consulting or director fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company, (iii) indemnification and advancement of expenses in connection with Actions that are disclosed in the SEC Reports, and (iv) other employee benefits, including equity awards, stock option agreements and restricted stock awards under any equity incentive plan or stock option plan of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="16" data-prefix="" data-suffix="" style="font-size: 10pt; font-family: Times New Roman; text-align: center;">16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(y)&nbsp;&nbsp;&nbsp;&nbsp;<u>Sarbanes Oxley Compliance</u>. The Company and the Subsidiaries are in compliance with any and all applicable requirements of the Sarbanes-Oxley Act of 2002, as amended, that are effective as of the date hereof, and any and all applicable rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof. The Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management&#8217;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management&#8217;s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&#8217;s rules and forms. The Company&#8217;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the &#8220;<u>Evaluation Date</u>&#8221;). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(z)&nbsp;&nbsp;&nbsp;&nbsp;<u>Certain Fees</u>. Other than payments to be made to the Manager, no brokerage or finder&#8217;s fees or commissions are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by this Agreement. The Manager shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions contemplated by this Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(aa)&nbsp;&nbsp;&nbsp;&nbsp;<u>No Other Sales Agency Agreement</u>. The Company has not entered into any other sales agency agreements or other similar arrangements with any agent or any other representative in respect of at the market offerings of the Shares.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="17" data-prefix="" data-suffix="" style="font-size: 10pt; font-family: Times New Roman; text-align: center;">17</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(bb)&nbsp;&nbsp;&nbsp;&nbsp;[RESERVED]</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(cc)&nbsp;&nbsp;&nbsp;&nbsp;<u>Listing and Maintenance Requirements</u>. The Common Stock is listed on the Trading Market and the issuance of the Shares as contemplated by this Agreement does not contravene the rules and regulations of the Trading Market. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration. Except as set forth in the SEC Reports, the Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading Market. Except as set forth in the SEC Reports, the Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently eligible for electronic transfer through the Depository Trust Company or another established clearing corporation and the Company is current in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in connection with such electronic transfer.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(dd)&nbsp;&nbsp;&nbsp;&nbsp;<u>Application of Takeover Protections</u>. The Company and the Board have taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti&#8209;takeover provision under the Company&#8217;s certificate of incorporation (or similar charter documents) or the laws of its state of incorporation that is or could become applicable to the Shares.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(ee)&nbsp;&nbsp;&nbsp;&nbsp;<u>Disclosure of Indebtedness in SEC Reports</u>. The SEC Reports set forth, as of the date of the respective quarter or year-end or other applicable date, as applicable, set forth in such SEC Report, all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, &#8220;<u>Indebtedness</u>&#8221; means (x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&#8217;s consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="18" data-prefix="" data-suffix="" style="font-size: 10pt; font-family: Times New Roman; text-align: center;">18</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(ff)&nbsp;&nbsp;&nbsp;&nbsp;<u>Tax Status</u>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(gg)&nbsp;&nbsp;&nbsp;&nbsp;<u>Foreign Corrupt Practices</u>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(hh)&nbsp;&nbsp;&nbsp;&nbsp;<u>Accountants</u>. The Company&#8217;s accounting firm is set forth in the SEC Reports. To the knowledge and belief of the Company, such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall express its opinion with respect to the financial statements to be included in the Company&#8217;s Annual Report for the fiscal year ending December 31, 2023.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<u>Regulation M Compliance</u>.&nbsp; The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Shares, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Shares, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Manager in connection with the Shares.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="19" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">19</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(jj)&nbsp;&nbsp;&nbsp;&nbsp;<u>FDA</u>. Except as disclosed in the SEC Reports, each product subject to the jurisdiction of the U.S. Food and Drug Administration (&#8220;<u>FDA</u>&#8221;) under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&#8220;<u>FDCA</u>&#8221;) that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &#8220;<u>Pharmaceutical Product</u>&#8221;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. Except as disclosed in the SEC Reports, there is no pending, completed or, to the Company's knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA, except where the failure to be in compliance would not have a Material Adverse Effect.&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(kk)&nbsp;&nbsp;&nbsp;&nbsp;<u>Stock Option Plans</u>. Each stock option granted by the Company under the Company&#8217;s stock incentive plan was granted (i) in accordance with the terms of the Company&#8217;s stock incentive plan and (ii) with an exercise price at least equal to the fair market value of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the Company&#8217;s stock incentive plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results or prospects.<u> </u></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(ll)&nbsp;&nbsp;&nbsp;&nbsp;<u>Cybersecurity</u>.&nbsp; (i)(x) To the Company&#8217;s knowledge, there has been no material security breach or other compromise of or relating to any of the Company&#8217;s or any Subsidiary&#8217;s information technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively, &#8220;<u>IT Systems and Data</u>&#8221;) and (y) the Company and the Subsidiaries have not been notified of any security breach or other compromise to its IT Systems and Data, in each case, except as would not, individually or in the aggregate, have a Material Adverse Effect; (ii) the Company and the Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except as would not, individually or in the aggregate, have a Material Adverse Effect; (iii)&nbsp;the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain and protect its material confidential information and the integrity, operation, redundancy and security of all IT Systems and Data, except where the failure to do so would not have a Material Adverse Effect; and (iv) the Company and the Subsidiaries have implemented commercially reasonable backup and disaster recovery technology consistent with industry standards in all material respects and practices.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="20" data-prefix="" data-suffix="" style="font-size: 10pt; font-family: Times New Roman; text-align: center;">20</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(mm)&nbsp;&nbsp;&nbsp;&nbsp;<u>Compliance with Data Privacy Laws</u>. (i)&nbsp;The Company and the Subsidiaries are, and at all times during the past three years were, in compliance with all applicable data privacy and security laws and regulations, including, as applicable, the European Union General Data Protection Regulation (&#8220;<u>GDPR</u>&#8221;) (EU 2016/679) (collectively, &#8220;<u>Privacy Laws</u>&#8221;); (ii)&nbsp;the Company and the Subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling and analysis of Personal Data (the &#8220;<u>Policies</u>&#8221;); (iii)&nbsp;the Company provides accurate notice of its applicable Policies to its customers, employees, third party vendors and representatives as required by Privacy Laws; and (iv)&nbsp;applicable Policies provide accurate and sufficient notice of the Company&#8217;s then-current privacy practices relating to its subject matter, and do not contain any material omissions of the Company&#8217;s then-current privacy practices, as required by Privacy Laws, except for, in each case, failure or noncompliance that would not result in a Material Adverse Effect.&nbsp;&#8220;<u>Personal Data</u>&#8221; means (i)&nbsp;a natural person&#8217;s name, street address, telephone number, email address, photograph, social security number, bank information, or customer or account number; (ii)&nbsp;any information which would qualify as &#8220;personally identifying information&#8221; under the Federal Trade Commission Act, as amended; (iii) &#8220;personal data&#8221; as defined by GDPR; and (iv)&nbsp;any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any identifiable data related to an identified person&#8217;s health or sexual orientation. (i)&nbsp;None of such disclosures made or contained in any of the Policies have been inaccurate, misleading, or deceptive in violation of any Privacy Laws and (ii)&nbsp;the execution, delivery and performance of this Agreement will not result in a breach of any Privacy Laws or Policies, except, in both cases, such as would not have a Material Adverse Effect.&nbsp; Neither the Company nor the Subsidiaries, (i)&nbsp;has received written notice of any actual or potential liability of the Company or the Subsidiaries under, or actual or potential violation by the Company or the Subsidiaries of, any of the Privacy Laws; (ii)&nbsp;is currently conducting or paying for, in whole or in part, any investigation, remediation or other corrective action pursuant to any regulatory request or demand pursuant to any Privacy Law; or (iii)&nbsp;is a party to any order, decree, or agreement by or with any court or arbitrator or governmental or regulatory authority that imposed any obligation or liability under any Privacy Law, except, in each case, such as would not have a Material Adverse Effect.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="21" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">21</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(nn)&nbsp;&nbsp;&nbsp;&nbsp;<u>Office of Foreign Assets Control</u>. Neither the Company nor any of its Subsidiaries, nor to the knowledge of the Company, any of the directors, officers or employees of the Company or its Subsidiaries, is an individual or entity that is, or is owned or controlled by an individual or entity that is: (i)&nbsp;the subject of any sanctions administered or enforced by the U.S. Department of Treasury&#8217;s Office of Foreign Assets Control, the United Nations Security Council, the European Union, Her Majesty&#8217;s Treasury, or other relevant sanctions authority (collectively, &#8220;<u>Sanctions</u>&#8221;), nor (ii)&nbsp;located, organized or resident in a country or territory that is the subject of Sanctions. Neither the Company nor any of its Subsidiaries will, directly or indirectly, knowingly use the proceeds of the transactions contemplated hereby, or lend, contribute or otherwise make available such proceeds to any Subsidiary, joint venture partner or other individual or entity: (i)&nbsp;to fund or facilitate any activities or business of or with any individual or entity or in any country or territory that, at the time of such funding or facilitation, is the subject of Sanctions or (ii)&nbsp;in any other manner that will result in a violation of Sanctions by any individual or entity (including any individual or entity participating in the transactions contemplated hereby, whether as underwriter, advisor, investor or otherwise). For the past five years, neither the Company nor any of its Subsidiaries has knowingly engaged in, and is not now knowingly engaged in, any dealings or transactions with any individual or entity, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(oo)&nbsp;&nbsp;&nbsp;&nbsp;<u>Money Laundering</u>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &#8220;<u>Money Laundering Laws</u>&#8221;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(pp)&nbsp;&nbsp;&nbsp;&nbsp;<u>FINRA Member Shareholders</u>. There are no affiliations with any FINRA member firm among the Company&#8217;s officers, directors or, to the knowledge of the Company, any five percent (5%) or greater stockholder of the Company, except as set forth in the Registration Statement, the Base Prospectus, any Prospectus Supplement or the Prospectus.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="22" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">22</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.&nbsp;&nbsp;&nbsp;&nbsp;<u>Agreements</u>. The Company agrees with the Manager that:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Right to Review Amendments and Supplements to Registration Statement and Prospectus</u>. During any period when the delivery of a prospectus relating to the Shares is required (including in circumstances where such requirement may be satisfied pursuant to Rule&nbsp;172, 173 or any similar rule) to be delivered under the Act in connection with the offering or the sale of Shares, the Company will not file any amendment to the Registration Statement or supplement (including any Prospectus Supplement) to the Base Prospectus unless the Company has furnished to the Manager a copy for its review prior to filing and will not file any such proposed amendment or supplement to which the Manager reasonably objects (provided, however, that the Company will have no obligation to provide the Manager any advance copy of such filing or to provide the Manager an opportunity to object to such filing if the filing does not name the Manager and does not relate to the transactions under this Agreement). The Company has properly completed the Prospectus in a form approved by the Manager and filed such Prospectus, as amended at the Execution Time, with the Commission pursuant to the applicable paragraph of Rule&nbsp;424(b) by the Execution Time and will cause any supplement to the Prospectus filed after the Execution Time to be properly completed in a form approved by the Manager and will file such supplement with the Commission pursuant to the applicable paragraph of Rule&nbsp;424(b) within the time period prescribed thereby and will provide evidence reasonably satisfactory to the Manager of such timely filing. The Company will promptly advise the Manager (i)&nbsp;when the Prospectus, and any supplement thereto, shall have been filed (if required) with the Commission pursuant to Rule&nbsp;424(b), (ii)&nbsp;when, during any period when the delivery of a prospectus (whether physically or through compliance with Rule&nbsp;172, 173 or any similar rule) is required under the Act in connection with the offering or sale of the Shares, any amendment to the Registration Statement shall have been filed or become effective (other than any annual report of the Company filed pursuant to Section 13(a) or 15(d) of the Exchange Act), (iii)&nbsp;of any request by the Commission or its staff for any amendment of the Registration Statement, or for any supplement to the Prospectus or for any additional information, (iv)&nbsp;of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or of any notice objecting to its use or the institution or threatening of any proceeding for that purpose and (v)&nbsp;of the receipt by the Company of any notification with respect to the suspension of the qualification of the Shares for sale in any jurisdiction or the institution or threatening of any proceeding for such purpose. The Company will use its reasonable best efforts to prevent the issuance of any such stop order or the occurrence of any such suspension or objection to the use of the Registration Statement and, upon such issuance, occurrence or notice of objection, to obtain as soon as possible the withdrawal of such stop order or relief from such occurrence or objection, including, if necessary, by filing an amendment to the Registration Statement or a new registration statement and using its reasonable best efforts to have such amendment or new registration statement declared effective as soon as practicable.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Subsequent Events</u>. If, at any time on or after an Applicable Time but prior to the related Settlement Date, any event occurs as a result of which the Registration Statement or Prospectus would include any untrue statement of a material fact or omit to state any material fact necessary to make the statements therein in the light of the circumstances under which they were made or the circumstances then prevailing not misleading, the Company will (i)&nbsp;notify promptly the Manager so that any use of the Registration Statement or Prospectus may cease until such are amended or supplemented; (ii)&nbsp;amend or supplement the Registration Statement or Prospectus to correct such statement or omission; and (iii)&nbsp;supply any such amendment or supplement to the Manager in such quantities as the Manager may reasonably request.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Notification of Subsequent Filings</u>. During any period when the delivery of a prospectus relating to the Shares is required (including in circumstances where such requirement may be satisfied pursuant to Rule&nbsp;172, 173 or any similar rule) to be delivered under the Act, any event occurs as a result of which the Prospectus as then supplemented would include any untrue statement of a material fact or omit to state any material fact necessary to make the statements therein in the light of the circumstances under which they were made not misleading, or if it shall be necessary to amend the Registration Statement, file a new registration statement or supplement the Prospectus to comply with the Act or the Exchange Act or the respective rules thereunder, including in connection with use or delivery of the Prospectus, the Company promptly will (i)&nbsp;notify the Manager of any such event, (ii)&nbsp;subject to Section 4(a), prepare and file with the Commission an amendment or supplement or new registration statement which will correct such statement or omission or effect such compliance, (iii)&nbsp;use its reasonable best efforts to have any amendment to the Registration Statement or new registration statement declared effective as soon as practicable in order to avoid any disruption in use of the Prospectus and (iv)&nbsp;supply any supplemented Prospectus to the Manager in such quantities as the Manager may reasonably request.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="23" data-prefix="" data-suffix="" style="font-size: 10pt; font-family: Times New Roman; text-align: center;">23</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Earnings Statements</u>. As soon as practicable, the Company will make generally available to its security holders and to the Manager an earnings statement or statements of the Company and its Subsidiaries which will satisfy the provisions of Section&nbsp;11(a) of the Act and Rule&nbsp;158. For the avoidance of doubt, the Company&#8217;s compliance with the reporting requirements of the Exchange Act shall be deemed to satisfy the requirements of this Section 4(d).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of Registration Statement</u>. Upon the request of the Manager, the Company will furnish to the Manager and counsel for the Manager, without charge, signed copies of the Registration Statement (including exhibits thereto) and, so long as delivery of a prospectus by the Manager or dealer may be required by the Act (including in circumstances where such requirement may be satisfied pursuant to Rule&nbsp;172, 173 or any similar rule), as many copies of the Prospectus and each Issuer Free Writing Prospectus and any supplement thereto as the Manager may reasonably request, provided that the Company&#8217;s obligation to provide such copies shall not apply to any filing available via EDGAR. The Company will pay the expenses of printing or other production of all documents relating to the offering.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Qualification of Shares</u>. The Company will arrange, if necessary, for the qualification of the Shares for sale under the laws of such jurisdictions as the Manager may designate and will maintain such qualifications in effect so long as required for the distribution of the Shares; provided that in no event shall the Company be obligated to qualify to do business in any jurisdiction where it is not now so qualified or to take any action that would subject it to service of process in suits, other than those arising out of the offering or sale of the Shares, in any jurisdiction where it is not now so subject.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(g)&nbsp;&nbsp;&nbsp;&nbsp;<u>Free Writing Prospectus</u>. The Company agrees that, unless it has or shall have obtained the prior written consent of the Manager, and the Manager agrees with the Company that, unless it has or shall have obtained, as the case may be, the prior written consent of the Company, it has not made and will not make any offer relating to the Shares that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a &#8220;free writing prospectus&#8221; (as defined in Rule&nbsp;405) required to be filed by the Company with the Commission or retained by the Company under Rule&nbsp;433. Any such free writing prospectus consented to by the Manager or the Company is hereinafter referred to as a &#8220;<u>Permitted Free Writing Prospectus</u>.&#8221; The Company agrees that (i)&nbsp;it has treated and will treat, as the case may be, each Permitted Free Writing Prospectus as an Issuer Free Writing Prospectus and (ii)&nbsp;it has complied and will comply, as the case may be, with the requirements of Rules&nbsp;164 and 433 applicable to any Permitted Free Writing Prospectus, including in respect of timely filing with the Commission, legending and record keeping.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="24" data-prefix="" data-suffix="" style="font-size: 10pt; font-family: Times New Roman; text-align: center;">24</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(h)&nbsp;&nbsp;&nbsp;&nbsp;<u>Subsequent Equity Issuances</u>. The Company shall not deliver any Sales Notice hereunder (and any Sales Notice previously delivered shall not apply during such two Business Days) for at least two (2) Business Days prior to any date on which the Company or any Subsidiary offers, sells, issues, contracts to sell, contracts to issue or otherwise disposes of, directly or indirectly, any other shares of Common Stock or any Common Stock Equivalents (other than the Shares), subject to Manager&#8217;s right to waive this obligation, provided that, without compliance with the foregoing obligation, the Company may issue and sell Common Stock pursuant to any employee equity plan, stock ownership plan or dividend reinvestment plan of the Company in effect from time to time and the Company may issue Common Stock issuable upon the conversion or exercise of Common Stock Equivalents outstanding from time to time.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Market Manipulation</u>. Until the termination of this Agreement, the Company will not take, directly or indirectly, any action designed to or that would constitute or that might reasonably be expected to cause or result in, under the Exchange Act or otherwise, stabilization or manipulation in violation of the Act, Exchange Act or the rules and regulations thereunder of the price of any security of the Company to facilitate the sale or resale of the Shares or otherwise violate any provision of Regulation M under the Exchange Act.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(j)&nbsp;&nbsp;&nbsp;&nbsp;<u>Notification of Incorrect Certificate</u>. The Company will, at any time during the pendency of a Sales Notice, advise the Manager promptly after it shall have received notice or obtained knowledge thereof, of any information or fact that would alter or affect in any material respect any opinion, certificate, letter and other document required to be provided to the Manager pursuant to Section&nbsp;6 herein.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(k)&nbsp;&nbsp;&nbsp;&nbsp;<u>Certification of Accuracy of Disclosure</u>. Upon commencement of the offering of the Shares under this Agreement (and upon the recommencement of the offering of the Shares under this Agreement following the termination of a suspension of sales hereunder lasting more than 30 Trading Days), and each time that (i) the Registration Statement or Prospectus shall be amended or supplemented, other than by means of Incorporated Documents, (ii) the Company files its Annual Report on Form 10-K under the Exchange Act, (iii) the Company files its quarterly reports on Form 10-Q under the Exchange Act, (iv) the Company files a Current Report on Form 8-K containing amended financial information of the Company (other than information that is furnished and not filed), if the Manager reasonably determines that the information in such Form 8-K is material, or (v) the Shares are delivered to the Manager as principal at the Time of Delivery pursuant to a Terms Agreement (such commencement or recommencement date and each such date referred to in (i), (ii), (iii), (iv) and (v) above, a &#8220;<u>Representation Date</u>&#8221;), unless waived by the Manager, the Company shall furnish or cause to be furnished to the Manager forthwith a certificate dated and delivered on the Representation Date, in form reasonably satisfactory to the Manager to the effect that the statements contained in the certificate referred to in Section 6 of this Agreement which were last furnished to the Manager are true and correct at the Representation Date, as though made at and as of such date (except that such statements shall be deemed to relate to the Registration Statement and the Prospectus as amended and supplemented to such date) or, in lieu of such certificate, a certificate of the same tenor as the certificate referred to in said Section 6, modified as necessary to relate to the Registration Statement and the Prospectus as amended and supplemented to the date of delivery of such certificate. Notwithstanding the foregoing, the requirement to provide a certificate under this Section 4(k) shall be waived for any Representation Date occurring at a time at which no Sales Notice is pending or a suspension is in effect, which waiver shall continue until the date the Company delivers a Sales Notice hereunder (which for such calendar quarter shall be considered a Representation Date). Notwithstanding the foregoing, if the Company subsequently decides to sell Shares following a Representation Date when the Company relied on such waiver and did not provide the Manager with a certificate under this Section 4(k), then before the Manager sells any Shares, the Company shall provide the Manager with such certificate dated the date of the Sales Notice.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="25" data-prefix="" data-suffix="" style="font-size: 10pt; font-family: Times New Roman; text-align: center;">25</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(l)&nbsp;&nbsp;&nbsp;&nbsp;<u>Bring Down Opinions; Negative Assurance</u>. Within five (5) Trading Days of each Representation Date for which the Company is obligated to deliver a certification pursuant to Section 4(k), unless waived by the Manager, the Company shall furnish or cause to be furnished forthwith to the Manager and to counsel to the Manager a written opinion of counsel to the Company (&#8220;<u>Company Counsel</u>&#8221;) addressed to the Manager and dated and delivered within five (5) Trading Days of such Representation Date, in form and substance reasonably satisfactory to the Manager, including a negative assurance representation, <u>provided, however</u>, that the requirement for the Company to furnish or cause to be furnished an opinion (but not with respect to a negative assurance representation) under this Section 4(l) shall be waived for any Representation Date other than a Representation Date on which a material amendment to the Registration Statement or Prospectus is made or the Company files its Annual Report on Form 10-K or a material amendment thereto under the Exchange Act, unless the Manager reasonably requests such deliverable required under this Section 4(l) in connection with a Representation Date upon which request such deliverable shall be delivered hereunder. Notwithstanding the foregoing, the requirement to provide an opinion or negative assurance representation under this Section 4(l) shall be waived for any Representation Date occurring at a time at which no Sales Notice is pending or a suspension is in effect, which waiver shall continue until the Company delivers a Sales Notice hereunder (which for such calendar quarter shall be considered a Representation Date). Notwithstanding the foregoing, if the Company subsequently decides to sell Shares following a Representation Date when the Company relied on such waiver and did not provide the Manager with an opinion and negative assurance representation under this Section 4(l), then before the Manager sells any Shares, the Company shall provide the Manager with such opinion and negative assurance representation dated the date of the Sales Notice.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="26" data-prefix="" data-suffix="" style="font-size: 10pt; font-family: Times New Roman; text-align: center;">26</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(m)&nbsp;&nbsp;&nbsp;&nbsp;<u>Auditor Bring Down </u>&#8220;<u>Comfort</u><u>&#8221;</u><u> Letter</u>. Within five (5) Trading Days of each Representation Date for which the Company is obligated to deliver a certification pursuant to Section 4(k), unless waived by the Manager, the Company shall cause (1)&nbsp;the Company&#8217;s auditors (the &#8220;<u>Accountants</u>&#8221;), or other independent accountants satisfactory to the Manager forthwith to furnish the Manager a letter, and (2)&nbsp;if requested by the Manager, the Chief Financial Officer of the Company forthwith to furnish the Manager a certificate, in each case dated within five (5) Trading Days of such Representation Date, in form reasonably satisfactory to the Manager, of the same tenor as the letters and certificate referred to in Section 6 of this Agreement but modified to relate to the Registration Statement and the Prospectus, as amended and supplemented to the date of such letters and certificate; provided, however, that the requirement for the Company to furnish or cause to be furnished a &#8220;comfort&#8221; letter under this Section 4(m) shall be waived for any Representation Date other than a Representation Date on which a material amendment to the Registration Statement or Prospectus is made or the Company files its Annual Report on Form 10-K or a material amendment thereto under the Exchange Act, unless the Manager reasonably requests such deliverable required under this Section 4(m) in connection with a Representation Date upon which request such deliverable shall be delivered hereunder. Notwithstanding the foregoing, the requirement to deliver or cause to be delivered one or more letters or certificates under this Section 4(m) shall at the request of the Company be waived for any Representation Date occurring at a time at which no Sales Notice is pending or a suspension is in effect, which waiver shall continue until the Company delivers a Sales Notice hereunder (which for such calendar quarter shall be considered a Representation Date). Notwithstanding the foregoing, if the Company subsequently decides to sell Shares following a Representation Date when the Company relied on such waiver and did not provide the Manager with a letter or certificate under this Section 4(m), then before the Manager sells any Shares, the Company shall provide the Manager with such letter or certificate dated the date of the Sales Notice.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(n)&nbsp;&nbsp;&nbsp;&nbsp;<u>Due Diligence Session</u>. Upon commencement of the offering of the Shares under this Agreement (and upon the recommencement of the offering of the Shares under this Agreement following the termination of a suspension of sales hereunder lasting more than 30 Trading Days), and at each Representation Date, unless waived by the Manager, the Company will conduct a due diligence session, in form and substance, reasonably satisfactory to the Manager, which shall include representatives of management and Accountants. The Company shall cooperate timely with any reasonable due diligence request from or review conducted by the Manager or its agents from time to time in connection with the transactions contemplated by this Agreement, including, without limitation, providing information and available documents and access to appropriate corporate officers and the Company&#8217;s agents during regular business hours, and timely furnishing or causing to be furnished such certificates, letters and opinions from the Company, its officers and its agents, as the Manager may reasonably request. The Company shall reimburse the Manager for Manager&#8217;s counsel&#8217;s fees in each such due diligence update session, up to a maximum of $2,500 per update.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(o)&nbsp;&nbsp;&nbsp;&nbsp;<u>Acknowledgment of Trading</u>. The Company consents to the Manager trading in the Common Stock for the Manager&#8217;s own account and for the account of its clients at the same time as sales of the Shares occur pursuant to this Agreement or pursuant to a Terms Agreement, provided such trading complies with applicable requirements of the Act, the Exchange Act and the Trading Market.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="27" data-prefix="" data-suffix="" style="font-size: 10pt; font-family: Times New Roman; text-align: center;">27</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(p)&nbsp;&nbsp;&nbsp;&nbsp;<u>Disclosure of Shares Sold</u>. The Company will disclose in its Annual Reports on Form&nbsp;10-K and Quarterly Reports on Form&nbsp;10-Q, as applicable, the number of Shares sold through the Manager under this Agreement, the Net Proceeds to the Company and the compensation paid by the Company with respect to sales of Shares pursuant to this Agreement during the relevant quarter; and, if required by any subsequent change in Commission policy or request, more frequently by means of a Current Report on Form 8-K or a further Prospectus Supplement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(q)&nbsp;&nbsp;&nbsp;&nbsp;<u>Rescission Right</u>. If, at any time on or after the time that a person has agreed to purchase Shares from the Company as the result of an offer to purchase solicited by the Manager pursuant to a Sales Notice but prior to the related Settlement Date, the Company or the Manager becomes aware that (i) the Registration Statement or the Prospectus included at the date of such sale any untrue statement of a material fact or an omission to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading or (ii) the conditions set forth in Section 6 have not been satisfied in connection with such sale, the Company will, prior to the related Settlement Date for such Shares, offer to such person the right to refuse to purchase and pay for such Shares.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(r)&nbsp;&nbsp;&nbsp;&nbsp;<u>Bring Down of Representations and Warranties</u>. Each acceptance by the Company of an offer to purchase the Shares hereunder, and each execution and delivery by the Company of a Terms Agreement, shall be deemed to be an affirmation to the Manager that the representations and warranties of the Company contained in or made pursuant to this Agreement are true and correct as of the date of such acceptance or of such Terms Agreement as though made at and as of such date, and an undertaking that such representations and warranties will be true and correct as of the Settlement Date for the Shares relating to such acceptance or as of the Time of Delivery relating to such sale, as the case may be, as though made at and as of such date (except that such representations and warranties shall be deemed to relate to the Registration Statement and the Prospectus as amended and supplemented relating to such Shares).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(s)&nbsp;&nbsp;&nbsp;&nbsp;<u>Reservation of Shares</u>. The Company shall ensure that there are at all times sufficient shares of Common Stock to provide for the issuance, free of any preemptive rights, out of its authorized but unissued shares of Common Stock or shares of Common Stock held in treasury, of the maximum aggregate number of Shares authorized for issuance by the Board pursuant to the terms of this Agreement. The Company will use its commercially reasonable efforts to cause the Shares to be listed for trading on the Trading Market and to maintain such listing.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(t)&nbsp;&nbsp;&nbsp;&nbsp;<u>Obligation Under Exchange Act</u>. During any period when the delivery of a prospectus relating to the Shares is required (including in circumstances where such requirement may be satisfied pursuant to Rule&nbsp;172, 173 or any similar rule) to be delivered under the Act, the Company will file all documents required to be filed with the Commission pursuant to the Exchange Act within the time periods required by the Exchange Act and the regulations thereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify; text-indent: 18pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="28" data-prefix="" data-suffix="" style="font-size: 10pt; font-family: Times New Roman; text-align: center;">28</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(u)&nbsp;&nbsp;&nbsp;&nbsp;<u>DTC Facility</u>. The Company shall cooperate with the Manager and use its reasonable efforts to permit the Shares to be eligible for clearance and settlement through the facilities of DTC.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(v)&nbsp;&nbsp;&nbsp;&nbsp;<u>Use of Proceeds</u>. The Company will apply the Net Proceeds from the sale of the Shares in the manner set forth in the Prospectus.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(w)&nbsp;&nbsp;&nbsp;&nbsp;<u>Filing of Prospectus Supplement</u>. If any sales are made pursuant to this Agreement which are not made in &#8220;at the market&#8221; offerings as defined in Rule 415, including, without limitation, any Placement pursuant to a Terms Agreement, the Company shall file a Prospectus Supplement describing the terms of such transaction, the amount of Shares sold, the price thereof, the Manager&#8217;s compensation, and such other information as may be required pursuant to Rule 424 and Rule 430B, as applicable, within the time required by Rule 424.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(x)&nbsp;&nbsp;&nbsp;&nbsp;<u>Additional Registration Statement</u>. To the extent that the Registration Statement is not available for the sales of the Shares as contemplated by this Agreement, the Company may file a new registration statement with respect to any additional shares of Common Stock necessary to complete such sales of the Shares and, upon the filing of such registration statement, shall cause such registration statement to become effective as promptly as practicable. After the effectiveness of any such registration statement, all references to &#8220;<u>Registration Statement</u>&#8221; included in this Agreement shall be deemed to include such new registration statement, including all documents incorporated by reference therein pursuant to Item&nbsp;12 of Form S-3, and all references to &#8220;<u>Base Prospectus</u>&#8221; included in this Agreement shall be deemed to include the final form of prospectus, including all documents incorporated therein by reference, included in any such registration statement at the time such registration statement became effective.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.&nbsp;&nbsp;&nbsp;&nbsp;<u>Payment of Expenses</u>. The Company agrees to pay the costs and expenses incident to the performance of its obligations under this Agreement, whether or not the transactions contemplated hereby are consummated, including without limitation: (i)&nbsp;the preparation, printing or reproduction and filing with the Commission of the Registration Statement (including financial statements and exhibits thereto), the Prospectus and each Issuer Free Writing Prospectus, and each amendment or supplement to any of them; (ii)&nbsp;the printing (or reproduction) and delivery (including postage, air freight charges and charges for counting and packaging) of such copies of the Registration Statement, the Prospectus, and each Issuer Free Writing Prospectus, and all amendments or supplements to any of them, as may, in each case, be reasonably requested for use in connection with the offering and sale of the Shares; (iii)&nbsp;the preparation, printing, authentication, issuance and delivery of certificates for the Shares, including any stamp or transfer taxes in connection with the original issuance and sale of the Shares; (iv)&nbsp;the printing (or reproduction) and delivery of this Agreement, any blue sky memorandum and all other agreements or documents printed (or reproduced) and delivered in connection with the offering of the Shares; (v)&nbsp;the registration of the Shares under the Exchange Act, if applicable, and the listing of the Shares on the Trading Market; (vi)&nbsp;any registration or qualification of the Shares for offer and sale under the securities or blue sky laws of the several states (including filing fees and the reasonable fees and expenses of counsel for the Manager relating to such registration and qualification); (vii)&nbsp;the transportation and other expenses incurred by or on behalf of Company representatives in connection with presentations to prospective purchasers of the Shares; (viii)&nbsp;the fees and expenses of the Company&#8217;s accountants and the fees and expenses of counsel (including local and special counsel) for the Company; (ix) the filing fee under FINRA Rule 5110; (x) the reasonable fees and expenses of the Manager&#8217;s counsel, not to exceed $50,000 (excluding any periodic due diligence fees provided for under Section 4(n)), which shall be paid upon the Execution Time; and (xi) all other costs and expenses incident to the performance by the Company of its obligations hereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="29" data-prefix="" data-suffix="" style="font-size: 10pt; font-family: Times New Roman; text-align: center;">29</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">6.&nbsp;&nbsp;&nbsp;&nbsp;<u>Conditions to the Obligations of the Manager</u>. The obligations of the Manager under this Agreement and any Terms Agreement shall be subject to (i)&nbsp;the accuracy of the representations and warranties on the part of the Company contained herein as of the Execution Time, each Representation Date, and as of each Applicable Time, Settlement Date and Time of Delivery, (ii)&nbsp;the performance by the Company of its obligations hereunder and (iii)&nbsp;the following additional conditions, except as set forth in Section 4(l) and Section 4(m) herein:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Filing of Prospectus Supplement</u>. The Prospectus, and any supplement thereto, required by Rule&nbsp;424 to be filed with the Commission have been filed in the manner and within the time period required by Rule&nbsp;424(b) with respect to any sale of Shares; each Prospectus Supplement shall have been filed in the manner required by Rule&nbsp;424(b) within the time period required hereunder and under the Act; any other material required to be filed by the Company pursuant to Rule&nbsp;433(d) under the Act, shall have been filed with the Commission within the applicable time periods prescribed for such filings by Rule&nbsp;433; and no stop order suspending the effectiveness of the Registration Statement or any notice objecting to its use shall have been issued and, to the Company&#8217;s knowledge, no proceedings for that purpose shall have been instituted or threatened.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of Opinion</u>. The Company shall have caused the Company Counsel to furnish to the Manager its opinion and negative assurance statement, dated as of such date and addressed to the Manager in form and substance reasonably acceptable to the Manager, which opinions and negative assurance statement shall be substantively similar to those required under Section 4(l) of this Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of Officer</u><u>&#8217;</u><u>s Certificate</u>. The Company shall have furnished or caused to be furnished to the Manager a certificate of the Company signed by the Chief Executive Officer or the President and the principal financial or accounting officer of the Company, dated as of such date, to the effect that the signers of such certificate have carefully examined the Registration Statement, the Prospectus, any Prospectus Supplement and any documents incorporated by reference therein and any supplements or amendments thereto and this Agreement and that:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt; text-align: justify; text-indent: 27pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;the representations and warranties of the Company in this Agreement are true and correct on and as of such date with the same effect as if made on such date and the Company has complied in all material respects with all the agreements and satisfied all the conditions on its part to be performed or satisfied at or prior to such date;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="30" data-prefix="" data-suffix="" style="font-size: 10pt; font-family: Times New Roman; text-align: center;">30</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt; text-indent: 27pt; text-align: justify;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;no stop order suspending the effectiveness of the Registration Statement or any notice objecting to its use has been issued and no proceedings for that purpose have been instituted or, to the Company&#8217;s knowledge, threatened; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt; text-align: justify; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt; text-indent: 27pt; text-align: justify;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;since the date of the most recent financial statements included in the Registration Statement, the Prospectus and the Incorporated Documents, there has been no Material Adverse Effect on the condition (financial or otherwise), earnings, business or properties of the Company and its subsidiaries, taken as a whole, whether or not arising from transactions in the ordinary course of business, except as set forth in or contemplated in the Registration Statement and the Prospectus.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of Accountants</u><u>&#8217;</u><u> </u>&#8220;<u>Comfort</u><u>&#8221;</u><u> Letter</u>. The Company shall have requested and caused the Accountants to have furnished to the Manager letters (which may refer to letters previously delivered to the Manager), dated as of such date, in form and substance satisfactory to the Manager, confirming that they are independent accountants within the meaning of the Act and the Exchange Act and the respective applicable rules and regulations adopted by the Commission thereunder and that they have performed a review of any unaudited interim financial information of the Company included or incorporated by reference in the Registration Statement and the Prospectus and provide customary &#8220;comfort&#8221; as to such review in form and substance satisfactory to the Manager.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(e)&nbsp;&nbsp;&nbsp;&nbsp;<u>No Material Adverse Event</u>. Since the respective dates as of which information is disclosed in the Registration Statement, the Prospectus and the Incorporated Documents, except as otherwise stated therein, there shall not have been (i)&nbsp;any change or decrease in previously reported results specified in the letter or letters referred to in paragraph&nbsp;(d) of this Section 6 or (ii)&nbsp;any change, or any development involving a prospective change, in or affecting the condition (financial or otherwise), earnings, business or properties of the Company and its subsidiaries taken as a whole, whether or not arising from transactions in the ordinary course of business, except as set forth in or contemplated in the Registration Statement, the Prospectus and the Incorporated Documents (exclusive of any amendment or supplement thereto) the effect of which, in any case referred to in clause&nbsp;(i) or (ii)&nbsp;above, is, in the sole judgment of the Manager, so material and adverse as to make it impractical or inadvisable to proceed with the offering or delivery of the Shares as contemplated by the Registration Statement (exclusive of any amendment thereof), the Incorporated Documents and the Prospectus (exclusive of any amendment or supplement thereto).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Payment of All Fees</u>. The Company shall have paid the required Commission filing fees relating to the Shares within the time period required by Rule&nbsp;456(b)(1)(i) of the Act without regard to the proviso therein and otherwise in accordance with Rules&nbsp;456(b) and 457(r) of the Act and, if applicable, shall have updated the &#8220;Calculation of Registration Fee&#8221; table in accordance with Rule&nbsp;456(b)(1)(ii) either in a post-effective amendment to the Registration Statement or in the manner specified by Rule 424(g) in a prospectus filed pursuant to Rule&nbsp;424(b).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="31" data-prefix="" data-suffix="" style="font-size: 10pt; font-family: Times New Roman; text-align: center;">31</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(g)&nbsp;&nbsp;&nbsp;&nbsp;<u>No FINRA Objections</u>. FINRA shall not have raised any objection with respect to the fairness and reasonableness of the terms and arrangements under this Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(h)&nbsp;&nbsp;&nbsp;&nbsp;<u>Shares Listed on Trading Market</u>. The Shares shall have been listed and admitted and authorized for trading on the Trading Market, and satisfactory evidence of such actions shall have been provided to the Manager.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Other Assurances</u>. Prior to each Settlement Date and Time of Delivery, as applicable, the Company shall have furnished to the Manager such further information, certificates and documents as the Manager may reasonably request.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">If any of the conditions specified in this Section 6 shall not have been fulfilled when and as provided in this Agreement, or if any of the opinions and certificates mentioned above or elsewhere in this Agreement shall not be reasonably satisfactory in form and substance to the Manager and counsel for the Manager, this Agreement and all obligations of the Manager hereunder may be canceled at, or at any time prior to, any Settlement Date or Time of Delivery, as applicable, by the Manager. Notice of such cancellation shall be given to the Company in writing or by telephone and confirmed in writing by email.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The documents required to be delivered by this Section 6 shall be delivered to the office of Ellenoff Grossman &amp; Schole LLP, counsel for the Manager, at 1345 Avenue of the Americas, New York, New York 10105, email: capmkts@egsllp.com, on each such date as provided in this Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">7.&nbsp;&nbsp;&nbsp;&nbsp;<u>Indemnification and Contribution</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Indemnification by Company</u>. The Company agrees to indemnify and hold harmless the Manager, the directors, officers, employees and agents of the Manager and each person who controls the Manager within the meaning of either the Act or the Exchange Act against any and all losses, claims, damages or liabilities, joint or several, to which they or any of them may become subject under the Act, the Exchange Act or other Federal or state statutory law or regulation, at common law or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement for the registration of the Shares as originally filed or in any amendment thereof, or in the Base Prospectus, any Prospectus Supplement, the Prospectus, any Issuer Free Writing Prospectus, or in any amendment thereof or supplement thereto, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading or result from or relate to any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement, and agrees to reimburse each such indemnified party for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action; <u>provided</u>, <u>however</u>, that the Company will not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon any such untrue statement or alleged untrue statement or omission or alleged omission made therein in reliance upon and in conformity with written information furnished to the Company by the Manager specifically for inclusion therein. This indemnity agreement will be in addition to any liability that the Company may otherwise have.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="32" data-prefix="" data-suffix="" style="font-size: 10pt; font-family: Times New Roman; text-align: center;">32</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Indemnification by Manager</u>. The Manager agrees to indemnify and hold harmless the Company, each of its directors, each of its officers who signs the Registration Statement, and each person who controls the Company within the meaning of either the Act or the Exchange Act, to the same extent as the foregoing indemnity from the Company to the Manager, but only with reference to written information relating to the Manager furnished to the Company by the Manager specifically for inclusion in the documents referred to in the foregoing indemnity; <u>provided</u>, <u>however</u>, that in no case shall the Manager be responsible for any amount in excess of the Broker Fee applicable to the Shares and paid hereunder. This indemnity agreement will be in addition to any liability which the Manager may otherwise have.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Indemnification Procedures</u>. Promptly after receipt by an indemnified party under this Section&nbsp;7 of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against the indemnifying party under this Section&nbsp;7, notify the indemnifying party in writing of the commencement thereof; but the failure so to notify the indemnifying party (i)&nbsp;will not relieve it from liability under paragraph&nbsp;(a) or&nbsp;(b) above unless and to the extent it did not otherwise learn of such action and such failure results in the forfeiture by the indemnifying party of substantial rights and defenses and (ii)&nbsp;will not, in any event, relieve the indemnifying party from any obligations to any indemnified party other than the indemnification obligation provided in paragraph&nbsp;(a) or (b)&nbsp;above. The indemnifying party shall be entitled to appoint counsel of the indemnifying party&#8217;s choice at the indemnifying party&#8217;s expense to represent the indemnified party in any action for which indemnification is sought (in which case the indemnifying party shall not thereafter be responsible for the fees and expenses of any separate counsel retained by the indemnified party or parties except as set forth below); <u>provided</u>, <u>however</u>, that such counsel shall be reasonably satisfactory to the indemnified party. Notwithstanding the indemnifying party&#8217;s election to appoint counsel to represent the indemnified party in an action, the indemnified party shall have the right to employ separate counsel (including local counsel), and the indemnifying party shall bear the reasonable fees, costs and expenses of such separate counsel if (i)&nbsp;the use of counsel chosen by the indemnifying party to represent the indemnified party would present such counsel with a conflict of interest, (ii)&nbsp;the actual or potential defendants in, or targets of, any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that there may be legal defenses available to it and/or other indemnified parties which are different from or additional to those available to the indemnifying party, (iii)&nbsp;the indemnifying party shall not have employed counsel reasonably satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of the institution of such action or (iv)&nbsp;the indemnifying party shall authorize the indemnified party to employ separate counsel at the expense of the indemnifying party. An indemnifying party will not, without the prior written consent of the indemnified parties, settle or compromise or consent to the entry of any judgment with respect to any pending or threatened claim, action, suit or proceeding in respect of which indemnification or contribution may be sought hereunder (whether or not the indemnified parties are actual or potential parties to such claim or action) unless such settlement, compromise or consent includes an unconditional release of each indemnified party from all liability arising out of such claim, action, suit or proceeding.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="33" data-prefix="" data-suffix="" style="font-size: 10pt; font-family: Times New Roman; text-align: center;">33</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Contribution</u>. In the event that the indemnity provided in paragraph&nbsp;(a), (b)&nbsp;or (c)&nbsp;of this Section&nbsp;7 is unavailable to or insufficient to hold harmless an indemnified party for any reason, the Company and the Manager agree to contribute to the aggregate losses, claims, damages and liabilities (including legal or other expenses reasonably incurred in connection with investigating or defending the same) (collectively &#8220;<u>Losses</u>&#8221;) to which the Company and the Manager may be subject in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and by the Manager on the other from the offering of the Shares; <u>provided</u>, <u>however</u>, that in no case shall the Manager be responsible for any amount in excess of the Broker Fee applicable to the Shares and paid hereunder. If the allocation provided by the immediately preceding sentence is unavailable for any reason, the Company and the Manager severally shall contribute in such proportion as is appropriate to reflect not only such relative benefits but also the relative fault of the Company on the one hand and of the Manager on the other in connection with the statements or omissions which resulted in such Losses as well as any other relevant equitable considerations. Benefits received by the Company shall be deemed to be equal to the total net proceeds from the offering (before deducting expenses) received by it, and benefits received by the Manager shall be deemed to be equal to the Broker Fee applicable to the Shares and paid hereunder as determined by this Agreement. Relative fault shall be determined by reference to, among other things, whether any untrue or any alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information provided by the Company on the one hand or the Manager on the other, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such untrue statement or omission. The Company and the Manager agree that it would not be just and equitable if contribution were determined by pro rata allocation or any other method of allocation which does not take account of the equitable considerations referred to above. Notwithstanding the provisions of this paragraph&nbsp;(d), no person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. For purposes of this Section&nbsp;7, each person who controls the Manager within the meaning of either the Act or the Exchange Act and each director, officer, employee and agent of the Manager shall have the same rights to contribution as the Manager, and each person who controls the Company within the meaning of either the Act or the Exchange Act, each officer of the Company who shall have signed the Registration Statement and each director of the Company shall have the same rights to contribution as the Company, subject in each case to the applicable terms and conditions of this paragraph&nbsp;(d).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="34" data-prefix="" data-suffix="" style="font-size: 10pt; font-family: Times New Roman; text-align: center;">34</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">8.&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall have the right, by giving written notice as hereinafter specified, to terminate the provisions of this Agreement relating to the solicitation of offers to purchase the Shares in its sole discretion at any time upon prior written notice. Any such termination shall be without liability of any party to any other party except that (i)&nbsp;with respect to any pending sale, through the Manager for the Company, the obligations of the Company, including in respect of compensation of the Manager, shall remain in full force and effect notwithstanding the termination and (ii)&nbsp;the provisions of Sections&nbsp;5, 6, 7, 8, 9, 10, 12, the second sentence of 13, 14 and 15 of this Agreement shall remain in full force and effect notwithstanding such termination.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;The Manager shall have the right, by giving written notice as hereinafter specified, to terminate the provisions of this Agreement relating to the solicitation of offers to purchase the Shares in its sole discretion at any time. Any such termination shall be without liability of any party to any other party except that the provisions of Sections&nbsp;5, 6, 7, 8, 9, 10, 12, the second sentence of 13, 14 and 15 of this Agreement shall remain in full force and effect notwithstanding such termination.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;This Agreement shall remain in full force and effect until such date that this Agreement is terminated pursuant to Sections&nbsp;8(a) or (b)&nbsp;above or otherwise by mutual agreement of the parties, provided that any such termination by mutual agreement shall in all cases be deemed to provide that Sections&nbsp;5, 6, 7, 8, 9, 10, 12, the second sentence of 13, 14 and 15 of this Agreement shall remain in full force and effect.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;Any termination of this Agreement shall be effective on the date specified in such notice of termination, provided that such termination shall not be effective until the close of business on the date of receipt of such notice by the Manager or the Company, as the case may be. If such termination shall occur prior to the Settlement Date or Time of Delivery for any sale of the Shares, such sale of the Shares shall settle in accordance with the provisions of Section 2(b) of this Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">(e)&nbsp;&nbsp;&nbsp;&nbsp;In the case of any purchase of Shares by the Manager pursuant to a Terms Agreement, the obligations of the Manager pursuant to such Terms Agreement shall be subject to termination, in the absolute discretion of the Manager, by prompt oral notice given to the Company prior to the Time of Delivery relating to such Shares, if any, and confirmed promptly by electronic mail, if since the time of execution of the Terms Agreement and prior to such delivery and payment, (i)&nbsp;trading in the Common Stock shall have been suspended by the Commission or the Trading Market or trading in securities generally on the Trading Market shall have been suspended or limited or minimum prices shall have been established on such exchange, (ii)&nbsp;a banking moratorium shall have been declared either by Federal or New York State authorities or (iii)&nbsp;there shall have occurred any outbreak or escalation of hostilities, declaration by the United States of a national emergency or war, or other calamity or crisis the effect of which on financial markets is such as to make it, in the sole judgment of the Manager, impractical or inadvisable to proceed with the offering or delivery of the Shares as contemplated by the Prospectus (exclusive of any amendment or supplement thereto).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="35" data-prefix="" data-suffix="" style="font-size: 10pt; font-family: Times New Roman; text-align: center;">35</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">9.&nbsp;&nbsp;&nbsp;&nbsp;<u>Representations and Indemnities to Survive</u>. The respective agreements, representations, warranties, indemnities and other statements of the Company or its officers and of the Manager set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by the Manager or the Company or any of the officers, directors, employees, agents or controlling persons referred to in Section&nbsp;7, and will survive delivery of and payment for the Shares.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">10.&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u>. All communications hereunder will be in writing and effective only on receipt, and will be mailed, delivered, or e-mailed to the addresses of the Company and the Manager, respectively, set forth on the signature page hereto.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">11.&nbsp;&nbsp;&nbsp;&nbsp;<u>Successors</u>. This Agreement will inure to the benefit of and be binding upon the parties hereto and their respective successors and the officers, directors, employees, agents and controlling persons referred to in Section&nbsp;7, and no other person will have any right or obligation hereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">12.&nbsp;&nbsp;&nbsp;&nbsp;<u>No Fiduciary Duty</u>. The Company hereby acknowledges that (a)&nbsp;the purchase and sale of the Shares pursuant to this Agreement is an arm&#8217;s-length commercial transaction between the Company, on the one hand, and the Manager and any affiliate through which it may be acting, on the other, (b)&nbsp;the Manager is acting solely as sales agent and/or principal in connection with the purchase and sale of the Company&#8217;s securities and not as a fiduciary of the Company and (c)&nbsp;the Company&#8217;s engagement of the Manager in connection with the offering and the process leading up to the offering is as independent contractors and not in any other capacity. Furthermore, the Company agrees that it is solely responsible for making its own judgments in connection with the offering (irrespective of whether the Manager has advised or is currently advising the Company on related or other matters). The Company agrees that it will not claim that the Manager has rendered advisory services of any nature or respect, or owe an agency, fiduciary or similar duty to the Company, in connection with such transaction or the process leading thereto.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">13.&nbsp;&nbsp;&nbsp;&nbsp;<u>Integration</u>. This Agreement and any Terms Agreement supersede all prior agreements and understandings (whether written or oral) between the Company and the Manager with respect to the subject matter hereof. Notwithstanding anything herein to the contrary, the letter agreement, dated November 16, 2023, by and between the Company and the Manager shall continue to be effective and the terms therein shall continue to survive and be enforceable by the Manager in accordance with its terms, provided that, in the event of a conflict between the terms of the letter agreement and this Agreement, the terms of this Agreement shall prevail.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">14.&nbsp;&nbsp;&nbsp;&nbsp;<u>Amendments; Waivers</u>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and the Manager. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="36" data-prefix="" data-suffix="" style="font-size: 10pt; font-family: Times New Roman; text-align: center;">36</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">15.&nbsp;&nbsp;&nbsp;&nbsp;<u>Applicable Law</u>. This Agreement and any Terms Agreement will be governed by and construed in accordance with the laws of the State of New York applicable to contracts made and to be performed within the State of New&nbsp;York. Each of the Company and the Manager: (i) agrees that any legal suit, action or proceeding arising out of or relating to this Agreement shall be instituted exclusively in New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York, (ii) waives any objection which it may have or hereafter to the venue of any such suit, action or proceeding, and (iii) irrevocably consents to the exclusive jurisdiction of the New York Supreme Court, County of New York, and the United States District Court for the Southern District of New York in any such suit, action or proceeding. Each of the Company and the Manager further agrees to accept and acknowledge service of any and all process which may be served in any such suit, action or proceeding in the New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York and agrees that service of process upon the Company mailed by certified mail to the Company&#8217;s address shall be deemed in every respect effective service of process upon the Company, in any such suit, action or proceeding, and service of process upon the Manager mailed by certified mail to the Manager&#8217;s address shall be deemed in every respect effective service process upon the Manager, in any such suit, action or proceeding. If either party shall commence an action or proceeding to enforce any provision of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its reasonable attorney&#8217;s fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">16.&nbsp;&nbsp;&nbsp;&nbsp;<u>Waiver of Jury Trial</u>. The Company hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement, any Terms Agreement or the transactions contemplated hereby or thereby.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">17.&nbsp;&nbsp;&nbsp;&nbsp;<u>Counterparts</u>. This Agreement and any Terms Agreement may be signed in one or more counterparts, each of which shall constitute an original and all of which together shall constitute one and the same agreement, which may be delivered in .pdf file via e-mail.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">***************************</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="37" data-prefix="" data-suffix="" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-align: center;">37</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">18.&nbsp;&nbsp;&nbsp;&nbsp;<u>Headings</u>. The section headings used in this Agreement and any Terms Agreement are for convenience only and shall not affect the construction hereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">If the foregoing is in accordance with your understanding of our agreement, please sign and return to us the enclosed duplicate hereof, whereupon this letter and your acceptance shall represent a binding agreement among the Company and the Manager.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Very truly yours,</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>BIOCARDIA, INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By: <u> /s/ Peter Altman</u><u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u><u>&nbsp;&nbsp;&nbsp;&nbsp; </u><br>
Name: Peter Altman, Ph.D.<br>
Title: President and Chief Executive Officer</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Address for Notice</u>:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">E-mail: [***]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The foregoing Agreement is hereby confirmed and accepted as of the date first written above.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>H.C. WAINWRIGHT &amp; CO., LLC</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By: <u>/s/ Edward D. Silvera</u><br>
Name: Edward D. Silvera<br>
Title: Chief Operating&nbsp;Officer</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Address for Notice</u>:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">430 Park Avenue<br>
New York, New York 10022<br>
Attention: Chief Executive Officer<br>
E-mail: <u>notices@hcwco.com</u></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="38" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">38</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div contenteditable="false" data-auto-pgnum="end">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Form of Terms Agreement</b><br>
<b>ANNEX I </b><br>
<b>BIOCARDIA, INC.</b><br>
<b>TERMS AGREEMENT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dear Sirs:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">BioCardia, Inc. (the &#8220;<u>Company</u>&#8221;) proposes, subject to the terms and conditions stated herein and in the At The Market Offering Agreement, dated December 6, 2023 (the &#8220;<u>At The Market Offering Agreement</u>&#8221;), between the Company and H.C. Wainwright &amp; Co., LLC (&#8220;<u>Manager</u>&#8221;), to issue and sell to Manager the securities specified in the <u>Schedule</u><u>&nbsp;</u><u>I</u> hereto (the &#8220;<u>Purchased Shares</u>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Each of the provisions of the At The Market Offering Agreement not specifically related to the solicitation by the Manager, as agent of the Company, of offers to purchase securities is incorporated herein by reference in its entirety, and shall be deemed to be part of this Terms Agreement to the same extent as if such provisions had been set forth in full herein. Each of the representations and warranties set forth therein shall be deemed to have been made at and as of the date of this Terms Agreement and the Time of Delivery, except that each representation and warranty in Section&nbsp;3 of the At The Market Offering Agreement which makes reference to the Prospectus (as therein defined) shall be deemed to be a representation and warranty as of the date of the At The Market Offering Agreement in relation to the Prospectus, and also a representation and warranty as of the date of this Terms Agreement and the Time of Delivery in relation to the Prospectus as amended and supplemented to relate to the Purchased Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">An amendment to the Registration Statement (as defined in the At The Market Offering Agreement), or a supplement to the Prospectus, as the case may be, relating to the Purchased Shares, in the form heretofore delivered to the Manager is now proposed to be filed with the Securities and Exchange Commission.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Subject to the terms and conditions set forth herein and in the At The Market Offering Agreement which are incorporated herein by reference, the Company agrees to issue and sell to the Manager and the latter agrees to purchase from the Company the number of shares of the Purchased Shares at the time and place and at the purchase price set forth in the <u>Schedule</u><u>&nbsp;</u><u>I</u> hereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If the foregoing is in accordance with your understanding, please sign and return to us a counterpart hereof, whereupon this Terms Agreement, including those provisions of the At The Market Offering Agreement incorporated herein by reference, shall constitute a binding agreement between the Manager and the Company.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>BIOCARDIA, INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 23pt;text-indent:-23pt;">By:&nbsp;&nbsp;&nbsp;&nbsp;<u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u><br>
Name:<br>
Title:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ACCEPTED as of the date first written above.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>H.C. WAINWRIGHT &amp; CO., LLC</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 23pt;text-indent:-23pt;">By:&nbsp;&nbsp;&nbsp;&nbsp;<u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u><br>
Name:<br>
Title:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 23pt;text-indent:-23pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ex_602766.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html><head>
	<title>ex_602766.htm</title>

	<!-- Generated by ThunderDome Portal - 12/4/2023 11:54:15 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<div>
<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: right;"><b>Exhibit 5.1</b></p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 75%; vertical-align: top;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><img alt="logo02.jpg" src="logo02.jpg"></p>
			</td>
			<td style="width: 25%; vertical-align: top;">
			<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Wilson Sonsini Goodrich &amp; Rosati<br>
			Professional Corporation</p>

			<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&nbsp;</p>

			<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">650 Page Mill Road<br>
			Palo Alto, California 94304-1050</p>

			<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&nbsp;</p>

			<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">o: 650.493.9300<br>
			f: 866.974.7329</p>
			</td>
		</tr>

</table>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&nbsp;</p>
</div>
</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">December&nbsp;6, 2023</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">BioCardia, Inc.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">320 Soquel Way</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Sunnyvale, California 94085</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Re:</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Registration Statement on Form S-3</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Ladies and Gentlemen:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">We have acted as counsel to BioCardia, Inc., a Delaware corporation (the &#8220;Company&#8221;), in connection with the registration of the offer and sale of up to $2,750,000 of shares (the &#8220;Shares&#8221;) of the Company&#8217;s common stock, $0.001 par value per share, pursuant to the Company&#8217;s registration statement on Form S-3 (File No. 333-275099), filed on October 19, 2023 and declared effective by the Securities and Exchange Commission (the &#8220;Commission&#8221;) on December&nbsp;5, 2023 (the &#8220;Registration Statement&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">The offering and sale of the Shares are being made pursuant to an At The Market Offering Agreement (the &#8220;Sales Agreement&#8221;) dated as of the date hereof by and between the Company and H.C. Wainwright &amp; Co., LLC.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">We have examined copies of the Sales Agreement, the Registration Statement, the base prospectus that forms a part thereof and the prospectus supplement thereto related to the offering of the Shares, which prospectus supplement is dated as of the date hereof and has been or will be filed by the Company in accordance with Rule 424(b) promulgated under the Securities Act of 1933 (the &#8220;Act&#8221;). We have also examined instruments, documents and records that we deemed relevant and necessary for the basis of our opinion hereinafter expressed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">In such examination, we have assumed (i) the authenticity of original documents and the genuineness of all signatures, (ii) the conformity to the originals of all documents submitted to us as copies, and (iii) the truth, accuracy, and completeness of the information, representations and warranties contained in the records, documents, instruments and certificates we have reviewed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Based on and subject to the foregoing, we are of the opinion that the Shares have been duly authorized by the Company and, when issued and delivered by the Company against payment therefor in accordance with the terms of the Sales Agreement, will be validly issued, fully paid and nonassessable.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">We express no opinion as to the laws of any other jurisdiction other than the federal laws of the United States of America and the General Corporation Law of the State of Delaware.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">We hereby consent to the use of this opinion as an exhibit to the Company&#8217;s Current Report on Form 8-K filed on or about the date hereof for incorporation by reference into the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Act or the rules and regulations of the Commission thereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:40%;margin-left:auto;margin-right:0pt;">

		<tr>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Sincerely,</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Wilson Sonsini Goodrich &amp; Rosati, P.C.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">WILSON SONSINI GOODRICH &amp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ROSATI,</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Professional Corporation</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;">AUSTIN&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BEIJING&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BOSTON&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BOULDER&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BRUSSELS&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; HONG KONG&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LONDON&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LOS ANGELES&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEW YORK&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PALO ALTO<br>
SALT LAKE CITY&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SAN DIEGO&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SAN FRANCISCO&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SEATTLE&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SHANGHAI&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; WASHINGTON, DC&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; WILMINGTON, DE</p>
</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>bcda-20231206.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 12/5/2023 3:18:01 AM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:bcda="http://www.bcda.com/20231206" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.bcda.com/20231206">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcda-20231206_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcda-20231206_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcda-20231206_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.bcda.com/20231206/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="bcda_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
<xsd:element abstract="true" id="bcda_CommonStockParValue0001CustomMember" name="CommonStockParValue0001CustomMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
<xsd:element abstract="true" id="bcda_WarrantToPurchaseCommonStockCustomMember" name="WarrantToPurchaseCommonStockCustomMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>bcda-20231206_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 12/5/2023 3:18:01 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.bcda.com/20231206/role/statement-document-and-entity-information" xlink:href="bcda-20231206.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.bcda.com/20231206/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
<link:loc xlink:href="bcda-20231206.xsd#bcda_CommonStockParValue0001CustomMember" xlink:label="bcda_CommonStockParValue0001CustomMember" xlink:type="locator"/>
<link:loc xlink:href="bcda-20231206.xsd#bcda_WarrantToPurchaseCommonStockCustomMember" xlink:label="bcda_WarrantToPurchaseCommonStockCustomMember" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bcda_CommonStockParValue0001CustomMember" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bcda_WarrantToPurchaseCommonStockCustomMember" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>bcda-20231206_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 12/5/2023 3:18:01 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
<link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
<link:label xlink:label="us-gaap_ClassOfStockDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain-label" xlink:type="arc"/>

<link:loc xlink:href="bcda-20231206.xsd#bcda_CommonStockParValue0001CustomMember" xlink:label="bcda_CommonStockParValue0001CustomMember" xlink:type="locator"/>
<link:label xlink:label="bcda_CommonStockParValue0001CustomMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CommonStockParValue0001 Custom [Member]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcda_CommonStockParValue0001CustomMember" xlink:to="bcda_CommonStockParValue0001CustomMember-label" xlink:type="arc"/>

<link:loc xlink:href="bcda-20231206.xsd#bcda_WarrantToPurchaseCommonStockCustomMember" xlink:label="bcda_WarrantToPurchaseCommonStockCustomMember" xlink:type="locator"/>
<link:label xlink:label="bcda_WarrantToPurchaseCommonStockCustomMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">WarrantToPurchaseCommonStock Custom [Member]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcda_WarrantToPurchaseCommonStockCustomMember" xlink:to="bcda_WarrantToPurchaseCommonStockCustomMember-label" xlink:type="arc"/>


</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>bcda-20231206_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 12/5/2023 3:18:01 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.bcda.com/20231206/role/statement-document-and-entity-information" xlink:href="bcda-20231206.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.bcda.com/20231206/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
<link:loc xlink:href="bcda-20231206.xsd#bcda_CommonStockParValue0001CustomMember" xlink:label="bcda_CommonStockParValue0001CustomMember" xlink:type="locator"/>
<link:loc xlink:href="bcda-20231206.xsd#bcda_WarrantToPurchaseCommonStockCustomMember" xlink:label="bcda_WarrantToPurchaseCommonStockCustomMember" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="bcda_CommonStockParValue0001CustomMember" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="bcda_WarrantToPurchaseCommonStockCustomMember" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>

<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>logo02.jpg
<TEXT>
begin 644 logo02.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M]J/@OQ38)JGASQ5KNAZ7J-JS%?-AE\/62MAE(96&<JP(*L 1R*X70]5^)?\
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M^P$NJ>)=%OM"\7_$;6;C6+^SU"S>UO;.WB/V:UADC<!E&R)Y@&&1]J/T'Z!
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'MO=_GZ'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140487076102688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 06, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">BIOCARDIA, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Dec.  06,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">001-38999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">23-2753988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">320 Soquel Way<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Sunnyvale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">94085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">226-0120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0000925741<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bcda_CommonStockParValue0001CustomMember', window );">CommonStockParValue0001 Custom [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BCDA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bcda_WarrantToPurchaseCommonStockCustomMember', window );">WarrantToPurchaseCommonStock Custom [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrant to Purchase Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BCDAW<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bcda_CommonStockParValue0001CustomMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bcda_CommonStockParValue0001CustomMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bcda_WarrantToPurchaseCommonStockCustomMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bcda_WarrantToPurchaseCommonStockCustomMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>bcda20231204_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bcda="http://www.bcda.com/20231206"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bcda-20231206.xsd" xlink:type="simple"/>
    <context id="d20238K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000925741</identifier>
        </entity>
        <period>
            <startDate>2023-12-06</startDate>
            <endDate>2023-12-06</endDate>
        </period>
    </context>
    <context id="d20238K_StatementClassOfStockAxis_CommonStockParValue0001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000925741</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcda:CommonStockParValue0001CustomMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-06</startDate>
            <endDate>2023-12-06</endDate>
        </period>
    </context>
    <context id="d20238K_StatementClassOfStockAxis_WarrantToPurchaseCommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000925741</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcda:WarrantToPurchaseCommonStockCustomMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-06</startDate>
            <endDate>2023-12-06</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20238K">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20238K">0000925741</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20238K">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20238K">2023-12-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20238K">BIOCARDIA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20238K">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20238K">001-38999</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20238K">23-2753988</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20238K">320 Soquel Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d20238K">Sunnyvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20238K">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20238K">94085</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20238K">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20238K">226-0120</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20238K">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20238K">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20238K">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20238K">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="d20238K_StatementClassOfStockAxis_CommonStockParValue0001">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20238K_StatementClassOfStockAxis_CommonStockParValue0001">BCDA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20238K_StatementClassOfStockAxis_CommonStockParValue0001">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="d20238K_StatementClassOfStockAxis_WarrantToPurchaseCommonStock">Warrant to Purchase Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20238K_StatementClassOfStockAxis_WarrantToPurchaseCommonStock">BCDAW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20238K_StatementClassOfStockAxis_WarrantToPurchaseCommonStock">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="d20238K">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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ME?QPS1FL:^P%\/M2*?-Z8G?ABDW4X7]02P,$%     @ IC"&5Y^@&_"Q @
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M\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @
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M-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U
M.EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*
M$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87
M_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( *8PAE<'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ IC"&5]OQDM7N    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ IC"&5YE<G",0!@  G"<  !,
M         ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "F
M,(97D3)(>M8$  !0%0  &               @($-"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ IC"&5Y^@&_"Q @  X@P   T
M         ( !&0T  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "F,(97EXJ[
M',     3 @  "P              @ 'U#P  7W)E;',O+G)E;'-02P$"% ,4
M    " "F,(97.JJBYT !   \ @  #P              @ '>$   >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ IC"&5R0>FZ*M    ^ $  !H
M     ( !2Q(  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ IC"&5V60>9(9 0  SP,  !,              ( !,!,  %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  >A0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="bcda20231204_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bcda.com/20231206/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>bcda-20231206.xsd</File>
    <File>bcda-20231206_def.xml</File>
    <File>bcda-20231206_lab.xml</File>
    <File>bcda-20231206_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="bcda20231204_8k.htm">bcda20231204_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "bcda20231204_8k.htm": {
   "nsprefix": "bcda",
   "nsuri": "http://www.bcda.com/20231206",
   "dts": {
    "schema": {
     "local": [
      "bcda-20231206.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "bcda-20231206_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "bcda-20231206_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bcda-20231206_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "bcda20231204_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 2,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 30,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 25
   },
   "report": {
    "R1": {
     "role": "http://www.bcda.com/20231206/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d20238K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcda20231204_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d20238K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcda20231204_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.bcda.com/20231206/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.bcda.com/20231206/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.bcda.com/20231206/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.bcda.com/20231206/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.bcda.com/20231206/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.bcda.com/20231206/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.bcda.com/20231206/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.bcda.com/20231206/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.bcda.com/20231206/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.bcda.com/20231206/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.bcda.com/20231206/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.bcda.com/20231206/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.bcda.com/20231206/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "bcda_WarrantToPurchaseCommonStockCustomMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bcda.com/20231206",
     "localname": "WarrantToPurchaseCommonStockCustomMember",
     "presentation": [
      "http://www.bcda.com/20231206/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WarrantToPurchaseCommonStock Custom [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.bcda.com/20231206/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.bcda.com/20231206/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "bcda_CommonStockParValue0001CustomMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bcda.com/20231206",
     "localname": "CommonStockParValue0001CustomMember",
     "presentation": [
      "http://www.bcda.com/20231206/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CommonStockParValue0001 Custom [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.bcda.com/20231206/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.bcda.com/20231206/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.bcda.com/20231206/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.bcda.com/20231206/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.bcda.com/20231206/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.bcda.com/20231206/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.bcda.com/20231206/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.bcda.com/20231206/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.bcda.com/20231206/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.bcda.com/20231206/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.bcda.com/20231206/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.bcda.com/20231206/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001437749-23-033718-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-23-033718-xbrl.zip
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MWT_\RD3I#2B(9T1([P7C48,W60]]/VNP"?GW^NHVZ&[!N9#?A^#)?#XG0=I
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M_3=),U50(?_G&+]2K:FT=^K&:;:%TN]$,A3H ?A?&RW9_;?"]"=02P,$%
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MK4I5V?S&[Y'EU-$L7Y4[ &=9>TP:_WT'/_>!?WJ]7Q2D_V4'7_(?4$L#!!0
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MG=A^J1TC,O(LP9Z#8Q]^WO$Q6YJ/,B/R'/RT]=_Q(6=/9.-]E9(TP,_!=,C
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MQ4'7$'P4.YV#S;AA)A$!AH<A@[VWM(:!=H(4ZI>/SG3+AY%@0Z4A<GI5:]>
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M&=*A5*UL\Q".KT@'5BDJB-3:,4*BS6,Z$9[75U[RU:JO.:F4&GN!QR-OT7#
M;R@V:0XF)!Y%3"_)&YFKA+6(BC6@UR6YDXPB))M@-X.B0S1NQ/V?C0>[F.1B
MQ%-B>XOS'-DU\4H4Q63=E^*5-2,6LS-<+#QAEM::R#R"'LIL^XBF3KF,T9<2
MC4HS&0(M0M68B2V(7XIT2ZP?*&1HPPSWZ::K=>O-HWB,,],80>3;DH9B.&?E
MXJ;IKH@>,\L1?F/-O&5R&VL$C!.STHDF"ID\Z[7'UIQ @)+L=7(6+(@TFID
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M[8/6=5JC4:]SR(I+M.5EJWO DNN6>XEH1?SEX+Q]R,)N[\-J86?/CPEV?EJ
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M?X,YO@3T)CU?1U[#%4ND+,E6R)=I7@7^%93S<CB5"FID@GK3(FD0%/:RK%J
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M$/!-L=JLDG.:/7M*[F*P K,D;H5AGD D^+P*TCO4X#D8:C@5!-VB,F9UYD6
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MZY:!CEKS#L=&SVAO@<#\#$/37WW$T/17A]#T(33]H8HG9V/%DY@PM[63D7D
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M!0EX+BDQ[U\\89/"-U6QWL6EF#W>,O>X]P$;W2+,2C4FF\UJI43K :47 G3
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MFJJ7CI40M)$,1[_;::";Z&5!$,T87+FJ"/<\8Z@D. DY^6!%-2]F6-  HQA
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M_*!T^^;XO]PPQQTN%IG9C .@X='7LX#/X3[+L(7#K:;W7ZU;HIZ]*IIP6[N
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M@BP!E??N0:"/TZ,G\#WPZ*?O1*2?1DSZ5,JDU6'H=Q?L)0<]L'VR1KI&MMP
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MOP-O*7D'?30E0-LN7^/8V*P\N>'MVIC]"DL020NZT7XBHQ[?X[3^N@M)AL&
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MRA=>NB%#\.W>R>D38WD%"0!6+NQ?QF11?SFKTFNU+2_:6?'F_U!+ 0(4 Q0
M   ( *8PAE>,S\&\J ,  $ /   1              "  0    !B8V1A+3(P
M,C,Q,C V+GAS9%!+ 0(4 Q0    ( *8PAE=,.>V3?P4  +<T   5
M      "  =<#  !B8V1A+3(P,C,Q,C V7V1E9BYX;6Q02P$"% ,4    " "F
M,(97!/Y#)\0&  !610  %0              @ &)"0  8F-D82TR,#(S,3(P
M-E]L86(N>&UL4$L! A0#%     @ IC"&5^M5(I0.!0  EC0  !4
M     ( !@!   &)C9&$M,C R,S$R,#9?<')E+GAM;%!+ 0(4 Q0    ( *8P
MAE=7T,C*RA4  $=Z   3              "  <$5  !B8V1A,C R,S$R,#1?
M.&LN:'1M4$L! A0#%     @ IC"&5^[:;^0Z"0  1"<   T
M ( !O"L  &5X7S8P,C<V-BYH=&U02P$"% ,4    " "F,(97>F/EMT"0  "E
M:0, #0              @ $A-0  97A?-C R.#,Q+FAT;5!+!08     !P '
+ +\!  ",Q0     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
